Автореферат и диссертация по медицине (14.00.03) на тему:Окислительный стресс при сахарном диабете 2-го типа и возможности его медикаментозной коррекции

Список использованных сокращений.

Введение.

Глава 1. Обзор литературы. Окислительный стресс при сахарном диабете типа 2 — общий патогенетический механизм тканевого повреждения, ведущий к прогрессированию ангиопатий, инсулинорезистентности и инсулиновой недостаточности.

1.1. 1. Сахарный диабет и окислительный стресс.

1.1.2. Что понимать под термином «окислительный стресс и в чем его особенность при сахарном'диабете типа 2?.

1.2:1. Окислительный стресс и диабетические ангиопатии.

Г. 2. 2. Конечные продукты неферментного гликирования в патогенезе диабетических ангиопатий.

1. 2. 3. Эндотелиальная дисфункция и окислительный стресс.

1. 2. 4. Окислительный стресс, ангиопатии и нарушения гемостаза . 43 1. 2. 5. Нарушение структурно-функциональных свойств клеточных мембран как причина сосудистых диабетических осложнений.

1. 2. 6. Окислительный стресс и роль Na+/H+ обмена в патогенезе диабетических ангиапатий.

1. 3. Окислительный стресс и инсулинорезистентность.

1.3. 1. Взаимодействие инсулина с рецептором и передача инсулинового сигнала в клетку.

1.3. 2 Роль окислительного стресса в развитии инсулинорезистентности.

1. 4. 1 Окислительный стресс и дисфункция |3-клеток при СД 2. 69 1. 4. 2. Механизмы глюкозотоксичности Р-клеток.

1. 4. 3 Липотоксичность и функция Р-клеток.

1. 5. Применение антиоксидантной терапии при СД 2.

1. 5. 1 Характеристика антиоксидантов, применяемых при сахарном диабете типа 2.

Глава 2. Материалы и методы исследования.

2. 1. Характеристика обследованных больных.

2. 2. Методы исследования.

2. 3. Методы статистической обработки.

Глава 3. Влияние компенсации углеводного обмена на липидотранспортную систему крови, свободнорадикальное окисление липопротеидов низкой плотности и активность ферментативной антиоксидантной системы при сахарном диабете типа 2.

Глава 4. Влияние компенсации углеводного обмена на нитриты и нитраты крови, активность ферментов антиоксидантной защиты эритроцитов, функциональную активность тромбоцитов при СД типа 2.

Исследование продукции оксида азота по уровню нитритов и нитратов плазмы при декомпенсации и компенсации углеводного обмена в зависимости от выраженности ПОЛ и активности ферменов АО защиты в эритоцитах.

Изучение влияния компенсации углеводного обмена на функциональные свойства тромбоцитов и реологию крови при сахарном диабете типа 2.

Глава 5. Применение антиоксидантных препаратов в комплексной терапии сахарного диабета типа 2.

5.1 Влияние пробукола на липидотранспортную систему крови, состояние углеводного обмена и показатели окислительного стресса при сахарном диабете типа 2.

5. 2 Влияние флавоноидов диквертина и танакана на оксидантный статус, показатели углеводного и липидного обмена, эндотелиальную дисфункцию и функциональную активность тромбоцитов у пациентов с сахарным диабетом типа 2.

5. 2. 1. Влияние антиоксидантной терапии на показатели углеводного обмена.

5. 2. 2. Влияние антиоксидантной терапии на холестерин-транспортную систему крови.

5.2.3. Влияние Танакана и Диквертина на ПОЛ и активность антиоксидантных ферментов эритроцитов.

5. 2. 4. Нитриты и нитраты плазмы крови на фоне приема Танакана и

Диквертина.

5.2. 5 Изучение функциональной активности тромбоцитов на фоне приема Танакана и Диквертина.

5. 2. 6. Влияние биофлавоноидов на активность Na^TH*" обменника у больных сахарным диабетом типа 2.

5.3. Влияние Танакана и Диквертина на течение диабетической препролиферативной ретинопатии.

5. 4. Изучение гипогликемизирующего действия Дибикора при сахарном диабете типа 2.

5. 5. Применение алликора при сахарном диабете типа 2 (двойное слепое плацебо контролируемое исследование).

Глава 6. Влияние аитиоксидантной терапии на чувствительность к инсулину.

6.1. Влияние диквертина на чувствительность к инсулину.

6. 2. Влияние пробукола на чувствительность к инсулину.

Глава 7. Влияние аитиоксидантной терапии на секреторные возможности инсулярного аппарата поджелудочной железы.

7. 1. Изучение влияния фенольного антиоксиданта пробукола на секреторные возможности инсулярного аппарата поджелудочной железы.

7. 2. Изучение влияния антиоксиданта флавоноидного ряда диквертина на секреторные возможности инсулярного аппарата поджелудочной железы.

1. Алиев О.И., Маслов М.Ю. //Антирадикальная активность экдистерон- и флавоноидсодержащих растительных экстрактов.// «Проблемы экспериментальной и клинической медицины». Томск. — 1996.- Вып.1. -С.45-47.

2. Архипова М.М.// Изучение роли оксида азота в патогенезе сосудистых заболеваний глаз.// Автореферат диссертации на соискание ученой степени кандидата медицинских наук. Москва.- 2001.- 16 с.

3. Архипова М.М., Нероев В.В.// L-аргинин в слезной жидкости больных с диабетической ретинопатией и возможная роль оксида азота в патогенезе ишемии сетчатки.// Вестник офтальмологии.- 2000. №2.-с.23-27.

4. Бакшинский П.П. // Эндотелины и оксид азота: их значение в регуляции глазного кровотока и внутриглазного давления и роль в патогенезе первичной глаукомы.// Вестник офтальмологии. — 1999. №3. - с.23.

5. Балаболкин М.И. // Диабетология.//- Москва. — 2000. Медицина.- 672с.

6. Балашова Т.С., Кубатиев А.А. //Влияние танакана на перекисное окисление липидов крови и агрегационные свойства тромбоцитов у больных инсулинзависимым сахарным диабетом.// Тер. Архив. 1998. -№12. - с.49-54.

7. Балашова Т.С., Барабой В.А.// Растительные фенолы и здоровье человека.// Москва. - 1984. - Наука. - 160 с.

8. Боднар П.И., Приступюк А.М.//Влияние компенсации сахарного диабета на процессы перекисного окисления. //Клиническая медицина. -1984.- №8. -с. 98-101.

9. Бородай А.В. // Танакан в комплексном лечении диабетической ретинопатии.// Диссертация на соискание ученой степени кандидатамедицинских наук. Москва - 2000.

10. Ю.Буйдина Т.А. // Изменение липидного состава эритроцитарных мембран при сахарном диабете // Автореф. дисс. . канд. мед. наук. Ярославль. -1991.-24 с.

11. П.Бурлакова Е.Б, Крашаков С.А, Храпова Н.Г.// Роль токоферолов в пероксидном окислении липидов биомембран. //Биологические мембраны. 1998. - 15(2). - с. 137-167.

12. Воскресенский О. Н., Бобырев В. Н. // Биоксиданты — облигатные факторы питания.// Вопр. мед. химии. — 1992. №4. - с. 21-26.

13. Выдыборец С.В.// Изменения эритроцитов при сахарном диабете (обзор).// Врачебное дело. 1990. - №2. - с.56-61.

14. Горбенко Н. И.// Молекулярные механизмы развития диабетических микроангиопатий и их фармакологическая коррекция./ЛЗопросы биологической, медицинской и фармацевтической химии. 2000. - №1. - с. 17.

15. Голиков П.П., Голиков А.П. // Роль оксида азота в патологии. //Международный Медицинский Журнал ТОП медицина. — 1999. №. 5. - с. 24 - 27.

16. Голубев А. Г.// Окись азота (N0) в ЦНС. // Бюллетень экспериментальной биологии и медицины. — 1994. Т. 117. - №. 2. - с. 201.

17. Гуревич К. Г., Шимановский Н. Л.// Оксид азота: биосинтез, механизмы действия, функции.// Вопросы биологической, медицинской и фармацевтической химии. 2000. - №4.- с.1.

18. Деянда Д.М.// Гиполипидемические и другие антиатерогенные эффекты церивастатина у больных ИБС с гиперлипидемией.// Автореф. дисс. . канд. мед. наук. - Москва. - 2000.- 24 с.

19. Джавадов С. А., Эйюбова А. А. // Количественный анализ фосфолипидного состава миокарда при экспериментальном сахарномдиабете: влияние тотальной ишемии.// Вопросы мед. химии. — 1994. -№2. с.12-19.

20. Доборджгинидзе Л.М., Грацианский Н.А.// Роль статинов в коррекции диабетической дислипидемии. // Сах. диабет. 2001. - №2.- с.41-47.

21. Докшина Г. А., Силаева Т.Ю., Ярцев Е. И. // Некоторые инсулиноподобные эффекты таурина.// Вопросы Медицинской Химии — 1976.-т. 22.- с.503-507.

22. Драпкина О.М., Задорожная О.О., Ивашкин В.Т.// Особенности синтеза оксида азота у больных инфарктом миокарда.// Клиническая медицина. 2000. №3. - с. 19-23.

23. Евграфов В.Ю.// Диабетическая ретинопатия: патогенез, диагностика, лечение.// Диссертация на соискание ученой степени доктора медицинских наук. Москва. - 1996.

24. Жамбалова Б.А.// Антиоксидантные свойства дигидрокверцетина и ликопина.// Автореф. дисс. . канд. биол. наук. Москва. — 1997.

25. ЗО.Зенков Н.К., Ланкин В.З., Меныцикова Е.Б.// «Окислительный стресс. Биохимические и патофизиологические аспекты».// Москва. — 2001. -МАИК "Наука/Интерпериодика". 343 стр.

26. Ишунина А.М.//Эффективность антиоксидантной терапии поздних диабетических осложнений сахарного диабета 2 типа.// Автореф. дисс. . канд. мед. наук. -2000. Москва.

27. Климов А.Н.// Липопротеиды плазмы крови и атеросклероз.// В кн. Дислипопротеидемии и Ишемическая Болезнь Сердца. Под ред.Чазова Е.И., Климова А.Н.//-Москва. 1980.- Медицина. - С. 11-24.

28. Климов А.Н., Никульчева Н.Г.// Обмен липидов и липопротеидов и его нарушения. // С-Пб. 1999. - «Питер». - 505 стр.

29. Колхир В. К., Тюкавкина Н. А., Быков В. А. и др.// Диквертин новое антиоксидантное и капилляропротекторное средство.// Хим. - фарм. Журнал. - 1995. - №9. - с.61-64.

30. Кубатиев А. А., Тюкавкина Н. А., Ядигарова 3. Т., Рудько И. А., Быков

31. В. А.// Влияние диквертина на содержание циклических нуклеотидов в тромбоцитах.// Бюлл. Эксперим. Биол. и Мед. 1999. - т. 128,- №9. с.267-269.

32. Кубатиев А. А., Ядигарова 3. Т., Рудько И. А., Тюкавкина Н. А., Быков В. А.// Подавление диквертином АДФ и тромбин-индуцированного накопления цитоплазматического кальция в тромбоцитах человека.// Хим.- фарм. журнал. 1999. - №12. - с. 3-4.

33. Кубатиев А.А., Ядигарова З.Т., Рудько И.А., Тюкавкина Н.А., Быков В.А.// Диквертин эффективный ингибитор агрегации тромбоцитов флавоноидной природы.// Вопросы биол. мед. и фарм. химии. — 1999. -№ 3. - с 47-50.

34. Кудрин А. В.// Микроэлементы и оксид азота — полифункциональные лиганды. //Вопросы биологической, медицинской и фармацевтической химии. 2000. - №1. - с. 17.

35. Ланкин В. 3., Котелевцева Н. В.// Степень окисленности мембранных фосфолипидов и активность микросомальной системы гидроксилирования холестерина в печени животных при атерогенезе. //Вопросы мед. химии. — 1981. т. 27 (1). — с. 133-136.

36. Ланкин В.З., Гуревич С.М., Бурлакова Е.Б .// В кн.: Биоантиокислители . 1975. - Наука. - Москва. - с.73-78.

37. Ланкин В.З., Закирова А.Н.// Перекиси липидов и атеросклероз. Свободно-радикальное окисление полиеновых липидов в крови больных ИБС. //Кардиология. 1980. - Т.20. - №7. - с.96-99.

38. Ланкин В.З., Лупанов В.П., Лякишев А.А., Ревенко В.М. // Окисление липопротеидов при ИБС.//Кардиология — 1991. Т.31. -№6 - с. 87-90.

39. Ланкин В.З., Тихазе А.К.//Свободнорадикальные процессы в норме и при заболеваниях сердечно-сосудистой системы.//Москва.-2000. 60 с.

40. Ланкин В.З., Тихазе А.К., Беленков Ю. Н.// Антиоксиданты в комплексной терапии: pro et contra.// Кардиология. 2004- т.44 - №2 - с. 72-81.

41. Ланкин В.З., Тихазе А.К., Беленков Ю. Н.// Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы. //Кардиология. 2000 - т. 40. - №7. - с. 48-61.

42. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. // Свободнорадикальные процессы в норме и при патологических состояниях (пособие для врачей)// Москва. 2001. - РКНПК МЗ РФ. - 78 стр.

43. Лукьянчук В.Д., Савченкова Л.В., Рыдлевский В.В., Белоусова И.П.//Роль ингибиторов фосфодиэстеразы цАМФ в фармакотерапии гипоксического синдрома. //Эксп. клин, фармакология. — 1998. -№6. -с.36-38.

44. Ляйфер А. И., Солун М. Н./ Система перекисного окисления липоидов — антиоксидантная защита и роль ее нарушений в патогенезе сахарного диабета и ангиопатий.// Пробл. эндокринол. 1993. - № 1. - с. 57-59.

45. Маеда X., Акаике Т.// Оксид азота и кислородные радикалы при инфекции, воспалении и раке.// Биохимия,- 1998. Т. 63. - вып. 7. - с. 1007- 1019.

46. Мазурина Н.К.// Современные данные о пролиферативном процессе при диабетической ретинопатии.//Вестник офтальмологии. -1999. №3.-с.15

47. Максимова О.В.//Липидный состав и уровень проницаемости эритроцитарных мембран у больных сахарным диабетом 1 типа. //Автореф. дисс. . канд. мед. наук. 1988.- Москва.

48. Максимова О.В., Солун М.Н.// Особенности липидного состава эритроцитарных мембран у больных сахарным диабетом.// Проблемы эндокринологии. — 1989. № 2. - с14-18.

49. Максина А.Г., Микаелян Н.П., Князев Ю.А.// Исследование с помощью спин-меченных жирных кислот структурных изменений в мембранах эритроцитов при сахарном диабете.// Биофизика. — 1992. Т.37. - Вып.2. - с. 306-3 09.

50. Маличенко С.Б.// Влияние полиненасыщенных жирных кислот ш-З на клиническое течение атеросклероза у больных инсулиннезависимым сахарным диабетом. //Автореф. дисс. . канд. мед. наук.- 1995. Москва.

51. Малышев И.Ю., Манухина Е.Б.// Стресс, адаптация и оксид азота. //Ж. патологической физиологии и экспериментальной терапии. 1998. - Т. 63.-вып. 7.-с. 992-1011.

52. Манухина Е. Б., Малышев И. Ю., Архипенко Ю. В.// Оксид азота в сердечно-сосудистой системе: роль в адаптационной защите. //Вестник Российской АМН.- 2000. №9. - с. 16.

53. Медведев Ю.В., Толстой А.Д. // Гипоксия и свободные радикалы в развитии патологических состояний организма.// Москва. 2000. - ООО «Терра-Календер и Промоушн». - 232 стр.

54. Меерсон Ф.З.// Патогенез стрессорных и ишемических повреждений сердца.// Москва. 1984. - «Медицина». - 240 стр.

55. Мельчинская Е. Н., Поповцева Щ. Н., Громнацкий Н. И. //Иммунологические аспекты применения Алисата у больных сахарным диабетом.// Бюлл. эксп. биол. мед.- 1997. № 11 - стр.595-597.

56. Микаелян Н.П., Максина А.Г., Князев Ю.А.// Состояние мембран эритроцитов при сахарном диабете. //Лабораторное дело. — 1991. №9. -с.41-44

57. Науменко В.Г.// Жирнокислотный спектр и перекисное окисление липидов в эритроцитах больных сахарным диабетом и диабетическими микроангиопатиями. // Автореф. дисс. . канд. мед. наук.- 1986. -Киев.

58. Невзорова В.А., Зуга М.В., Гельцер Б.И.// Роль окиси азота в регуляции легочных функций. //Терапевтический архив. 1997. - №. 3. - с. 68 - 73.

59. Патрсон Д.С.// Биологические мембраны.//Москва. 1978. - Атомиздат.

60. Поленов С.А.// Окись азота в регуляции функций желудочно-кишечного тракта.//Российский журнал гастроэнтерологии, гепатологии, колопроктологии.- 1998. №1. - с. 53-61.

61. Прайор У.// Роль свободнорадикальных реакций в биологических системах// в книге: Свободные радикалы в биологии (пер. с англ.)-Москва. 1979.- «Мир».- т. 1. - с.13-67.

62. Преображенский Д.В., Махмутходжаев С.А.// Влияние сахарного диабета на развитие атеросклероза (обзор).// Кардиология. 1987. -№3.-с.116-121.

63. Реутов В.П., Сорокина Е.Г.// NO-синтазная и нитритредуктазная компоненты цикла оксида азота. //Биохимия. 1998. - Т.63. - вып.7. -с. 1029- 1040.

64. Савченкова Л.В.//Кверцитин: фармакология и фармакотерапия (обзор). // Фармакология и токсикология. — 1991. Вып.26. - с.73-79.

65. Смирнова Е.Н. //Липидный обмен, синдром пероксидации и урикемия у больных сахарным диабетом при его сочетании с ИБС.// Автореф. дисс. . канд. мед. наук. 1989. - Пермь.

66. Собенин И. А., Орехов А. Н.// Положительные результаты первичной профилактики атеросклероза и атеросклеротических заболеваний // Росс. Кардиол. Журн.- 1999. №2- стр. 17-21

67. Соколов Е. И.//Сахарный диабет и атеросклероз.//Москва. —1996. -404с.

68. Сокольчик И.Г.//Влияние некоторых биофлавоноидов на неферментативную антиоксидантную защиту.// Здравоохранение Белоруссии. 1992. - №2. - с.47-49.

69. Тарусов Б. Н.//Физико-химические механизмы биологического действия ионизирующих излучений.// Усп. совр. Биологии. 1957. -44(2).- с. 171-185.

70. Тихазе А.К., Ланкин В.З., Михин В.П., Ревенко В.М., Лупанов В.П. // Тер. архив. 1997. - №9. - с. 35-41.

71. Томилова Е.Н.// Роль структурно-функциональных изменений мембран эритроцитов в механизмах развития ангиопатий у больных инсулинзависимым сахарным диабетом и их фармакологическая коррекция.// Автореф. дисс. . канд. мед. наук.- 1998. Москва.

72. Топчиашвили В.3.//Влияние различных видов сахароснижающей терапии на липидный спектр плазмы крови у больных инсулин-независимым сахарным диабетом с вторичной резистентностью к сульфаниламидным препаратам.//Автореф. дисс. канд. мед. наук. 1995.

73. Тюкавкина Н.А.// Коррекция гемореологических расстройств при остром инфаркте миокарда у крыс с комплексом диквертина и аскорбиновой кислоты.// Вопросы биологической, медицинской и фармацевтической химии.- 2000. №2. - с. 14.

74. Тюкавкина Н.А., Руленко И.А., Колесник Ю.А //Природные флавоноиды как пищевые антиоксиданты и биологически активные добавки.// Вопросы питания. 1996. - №2. - с. 33-38.

75. Фам Тхи Май. // Фосфолипидный состав липопротеидов высокой плотности у больных ишемической болезнью сердца.// Автореф. дисс. . канд. мед. наук. 1983. - Москва.

76. Хорченко В.И., Иоффина О.Б., Куперберг Е.Б. и др.//К вопросу о современной трактовке факторов риска болезней системы кровообращения связанной с атеросклерозом. // Ангиология и сосудистая хирургия.- 1998.- №2.- с.137-146.

77. Шерстнев М.П., Атанаев Т.Б., Владимиров Ю.А. //Биофизика. 1989.- том 34. с. 684-687.

78. Эммануэль Н. М., Липчина Л. П.// Лейкоз у мышей и особенности его развития при воздействии ингибиторов цепных окислительных процессов. //Доклады АН СССР. 1958. - 121(1): 141-144.

79. Abdel-Wahab УН, O'Harte FP, Ratcliff Н, McClenaghan NH, Barnett CR, Flatt PR.//Glycation of insulin in the islets of Langerhans of normal and diabetic animals. // Diabetes-1996.- v.45. — p.1489-1496.

80. Accili D, Cama A, Barbetti F, Kadowaki H, Kadowaki T, Taylor SI// Insulin resistance due to mutations of the insulin receptor gene: an overview. // J Endocrinol Invest- 1992. v. 15. — p. 857-864.

81. Adler V, Yin Z, Tew KD, Ronai Z//Role of redox potential and reactive oxygen species in stress signaling. //Oncogene. 1999. - v. 18.- p.6104-6111

82. Aguirre V, Uchida T, Yenush L, Davis R, White MF// The c-jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). // J Biol Chem 2000. — v. 275. p. 9047-9054.

83. Ahmad F, Azevedo Л, Cortright R, Dohm GL, Goldstein BJ.// Alterations in skeletal muscle protein-tyrozine phosphatase activity and expression in insulin-resistant human obesity and diabetes.//J. Clin. Invest. 1997. - v. 100. -p. 449-459.

84. Ackermann D., Hemsen H. A //J. Physiol Chem. -1935. v. 235. -p.l 15-121

85. Almind K, Doria A, Kahn CR. // Putting the genes for type П diabetes on the map.// Nat Med. 2001. - v. 7. - p. 277-279.

86. Alvarez J., Carcia-Sancho J., Molinedo F. //Intracellular Ca2+ potentiates Na/H exchange and cell differentiation induced by phorbol ester in U937 cells. // Eur.J.Biochem. 1989. -v. 183. -p.709-714.

87. Andrea JE, Walsh MP.// Protein kinase С of smooth muscle. //Hypertension. 1992. - v. 20. - p. 585-595.

88. Anonym // The role of antioxidants in diabetes//VERIS Res. Summary -1998.-May.-8p.

89. Anderson JW, Gowri MS, Turner J, Nichols L, Diwadkar VA, Chow CK, Oelgen PR.// Antioxidant Supplementation effects on low-density lipoprotein oxidation for individuals with type 2 Diabetes mellitu // J Am Coll Nutrition. 1999. - v. 18.-p. 451-461.

90. Arai K, Maguchi S, Fujii S, Ishibashi H, Oikawa K, Taniguchi N.// Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. //J. Biol. Chem. 1987. — v. 262. -p. 16969-16972.

91. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T,

92. Takahashi К, Shichiri M, Horiuchi S. // Macrophage scavender receptor mediates the endocytic uptake and degradation of advanced glycation end products of Maillard reaction.//Eur. J. Biochem. 1995. - v. 230. - p.408-15.

93. Armstrong A.M.; Chestnutt J.E.; Gormley M.J., Young I.S. //The effect of dietary treatment on lipid peroxidation and antioxidant status in newly diagnosed noninsulin dependent diabetes. // Free Radic. Biol. Med. — 1996. -v. 21.-p. 719-726.

94. Arner P., Pollare Т., Lithell H., Livingston J. N. // Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 diabetes mellitus // Diabetologia. 1987. - v. 30. - p. 437-440.

95. Astley S, Langrish-Smith A, Southon S. and Sampson M. //Vitamin E Supplementation and Oxidative Damage to DNA and Plasma LDL in Type 1 Diabetes. //Diabetes Care 1999. - v. 22. - p. 16261631.

96. Augusti К. Т., Mathew P. T.// Effect of allicin on certain enzymes of liver after a short term feeding to normal rats.// Experientia. 1975. —v. 31.-p. 148-149.

97. Augusti К. Т., Sheela C. G. // Antiperoxide effect of S-allyi cysteine sulfoxide an Insulin secretagogue in diabetic rats.// Experientia . — 1996. v. 52.-p. 115-120.

98. Babiy AV. Gebicky JM, Sullivan DR. // Increased oxidazibility of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation.//Biochem Pharmacol. 1992. - v.43. - p. 995-1000.

99. Baldwin Jr AS. //The transcription factor NF-«B and human disease.// J Clin Invest. 2001. - v. 107. - p.3-6.

100. Barnes PJ, Karin M. // Nuclear factor-«B: a pivotal transcription factor in chronic inflammatory diseases.//N Engl J Med. 1997.- v. 336. — p. 10661071.

101. Baskaran S., Balasubramanian K.A.// Effect of methylglyoxal on protein thiol and amino groups in isolated rat enterocyres and activity of various brush border enzymes.// Indian J Biochem Biophys.- 1990. — v. 27. -p. 13-17.

102. Baynes JW, Thorpe SR. // Glycoxidation and lipoxidation in atherogenesis. //Free Radic Biol Med. 2000. - v. 28. - p. 1708-1716.

103. Baynes J. W., Thorpe S. R. // The role of oxidative stress in diabetic complications. //Curr. Opin. Endocrinol. 1997. - v.3. - p. 277-284

104. Baynes J.W. Role of oxidative stress in development of complications in diabetes.// Diabetes. 1991. - v. 40. - p. 405-412.

105. Baynes J.W.Thorpe S.R. //The role of oxidative stress in diabetic complications. // Diabetes. 1999. - v.48. - p. 1-9.

106. Beauchamp C., Fridovich I.//Analyt. Biochem. 1971. - v.44. - p. 276-287.

107. Beckman JS, Koppenol WH. //Nitric oxide, superoxide and peroxynitrite: the good, the bad, and the ugly. // Am J Physiol. 1996. v.271 (Cell Physiol 40). С 1424-C1437.

108. Begum H., Bari M. A. // Effect of garlic oil on the pancreas of experimental diabetes in guineapigs. // Bangladesh Med. Res. Counc. Bull. — 1985.-v. ll-p.64- 68.

109. Bierenbaum ML, Noonan FJ, Machlin LJ, Machlin S, Stier A, Watson PB, Naso AM,Fleischman Al. //The effect of supplemental Vitamin E on serumperemeters in diabetics, post-coronary and normal subjects// Nutr Rep Internatl. 1985. - v. 31.-p. 1171-1180.

110. Beisswenger P, Howell S, Smith K, Szwergold B.// Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes.// Biochim Biophys Acta. — 2003. v. 1637. -p. 98-106.

111. Beisswenger P, Howell S, Touchette A, Lai S, Szwergold B.// Metformin reduces systemic methylglyoxal levels in type 2 diabetes. //Diabetes. 1999. -v.48.-p. 198-202.

112. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. // The adipocyte-secreted protein АсгрЗО enhances hepatic insulin action. //Nat Med. — 2001. v.7. - p. 947-953.

113. Berg AH, CombsTP, Scherer PE.// ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism.// Trends Endjcrinol Metab. — 2002. -v. 13.-p. 84-89.

114. Berthezene F. //Non-insulin dependent diabetes and reverse cholesterol transport. //Atherosclerosis. 1996. - v. 124. - p. S39-S42.

115. Bhuyan K.C., Bhuyan D.K. // Superoxide dismutase of the eye. Relative functions of superoxide dismutase and catalase in protecting the ocular lens from oxidative damage./ZBiochim. Biophys. Acta. 1978. — v. 542. —p.28-38.

116. Bierhaus A, Hofmami MA, Ziegler R, Nawroth PP. // AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept.// Cardiovasc Res. 1998. - v. 37. - p. 586-600.

117. Biewenga GP, Haenen GR, Bast A. // The pharmacology of the antioxidant lipoic acid. // Gen Pharmacol. — 1997. — v. 29. — p. 315—331.

118. Bird M.I., Nunn P.B., Lord L.A. //Formation of glycine and aminoacetone from L-treonine by rat liver mitochondria.// Biochim. Biophys. Acta. 1984. -v. 802.-p. 229-236.

119. Birnbaum MJ //Turning down insulin signaling.// J Clin Invest. 2001. — v. 108.-p. 655-659.

120. Block G. & L. Langseth. //Antioxidant vitamins and disease prevention.// Food Technol. J. 1994. - p.80-84.

121. Bobik A., Crooms A., Little P.J., Cragoe E.J. //Ethylisopropylamilorid-sensitive pH control mechanisms modulate vascular smooth muscle cell growth. // Am.J.Physiol. 1991. - v. 260. - C581-C588.

122. Boden G, Ruiz J, Kim С J, Chen X// Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects.// Am J Physiol. 1996.-v. 270. -E251-E258.

123. Boland MP, CNeil LA. // Ceramide activates NFkB by inducing the processing of рЮ5. //J Biol Chem. 1998. - v. 273. - p.15494-15495.

124. Bono A, Caimi G, Catania A, Sarno A, Pandolfo L.// Red cell peroxide metabolism in diabetes mellitus.//Horm Metab Res. — 1987. — v. 19.- p.264-6.

125. Boveris A. // Mitochondrial production of superoxide radical and hydrogen peroxide.// Adv Exp Med Biol. 1977. - v. 78. - p. 67-82.

126. Boveris A. //Determination of the production of superoxide radicals and hydrogen peroxide in mitochondria.//Methods Enzymol. — 1984- v. 105 p. 429-435.

127. Brady M. J., Nairn A. C., Saltiel A. R. // The regulation of glycogen synthase by protein phosphatase 1 in3T3-Ll adipocytes. Evidence for a potential role for DARPP-32 in insulin action.// J. Biol. Chem. 1997. - v. 272.-p. 29698-29703.

128. Brett J, et al// Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.//Am J Pathol. 1993. -v.143. —p. 1699-1712.

129. Briaud I, Kelpe CL, Johnson LM, Tran PO, Poitout V //Differential effects of hyperlipidemia on insulin secretion in islets of Langerhans from hyperglycemic versus normoglycemic rats.// Diabetes 2002. — v. 51. - p. 662-668.

130. Briaud I, Rouault C, Reach G, Poitout V// Long-term exposure of isolated rat islets of Langerhans to supraphysiologic glucose concentrations decreases insulin mRNA levels. //Metabolism 1999. - v. 48. - p. 319-323

131. Brown W.V.J/ Lipoprotein disorders in diabetes mellitus // Med. Clin. North. Am. 1994. - v.78. - p. 143-161.

132. Brownlee M. // Biochemistry and molecular cell biology of diabetic complications.// Nature 2001. - v. 414. - p.813-820.

133. Brownlee M, Cerami A, Vlassara H //Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. //N Engl J Med. -1988. -v. 318. p. 1315-1320.

134. Brownlee M. //Glycation and Diabetic Complications (Lilly Lecture). //Diabetes 1994.-v. 43.-p. 836-841.

135. Brownlee M. //Advanced protein glycosylation in diabetes and aging. //Ann. Rev. Med. 1996. - v.46. - p. 223-234.

136. Brownlee M. // Negative consequence of glycation.// Metadolism. 2000. - v.49 (Suppl. 1).-p. 9-13.

137. Brunauer L.S.; Moxness M.S.; Huestis W.H. // Hydrogen peroxide oxidation induces the transfer of phospholipids from the membrane into the cytosol of human erythrocytes. //Biochemistry. -1994. v. 334. - p. 527-532.

138. Bryszewska M., Zavodnik I.B.; Niekurzak A.; Szosland К.// Oxidative processes in red blood cells from normal and diabetic individuals. //Biochem. Mol. Biol. Int. 1995. - v. 37. - p. 345-354.

139. Bucala R, Cerami A. // Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. //Adv Pharmacol. 1992. -v.23.-p.l-34.

140. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. // Lipid advanced glycosylation: pathway for lipid oxidation in vivo. // Proc Natl Acad Sci USA. 1993. - v. 90. - p. 6434-6438.

141. Bucala R, Tracey KJ, Cerami A. // Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes.// Diabetologia. 1991. - v. 87. - p. 432-438.

142. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM Stern MP. //Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. // Archives of Internal Medicine. 1999. - v.159. - p. 1450-1456.

143. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA & Butler PC. // Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. // Diabetes 2003. - v.52. - p. 102-110.

144. Caballero В// Vitamin E improves the action of insulin. //Nutr Rev. -1993.-v. 51.-p. 339-340.

145. Cadenas E, Davies KJ// Mitochondrial free radical generation, oxidative stress, and aging. // Free Radic Biol Med. 2000. - v. 29. - p. 222-230.

146. Cahill GF, Etzwiler DD, Freinkel N. // Blood glucose control in diabetes.// N. Engl. J. Med. 1976. - v. 294. - p. 1004-1005.

147. Campbell I.W. // Need for intencive, early glycemic control in patient with type 2 diabetes. //Br. J.Cardiol. 2000. - v. 7. - p. 625-631.

148. Candiloros H., Zeghari N., Zeigler O. et al.// Hyperinsulinemia is related to phospholipid composition and membrane fluidity changes in obese nondiabetic women. // J.Clin. Endocrinol. Metab. -1996.- v.81. p. 2912-18.

149. Cameron N.E., Cotter M.A. // Metabolic and vascular factors in the pato-genesis" of diabetic neuropathy .//Diabetes. 1997. -v.46(Suppl. 2) - S 31-37.

150. Candiloros H., Zeghari N., Zeigler O. // Hyperinsulinemia is related to phospholipid composition and membrane fluidity changes in obese nondiabetic women. // J.Clin. Endocrinol. Metab. 1996. - v.81- p. 2912- 18.

151. Carr S.J.; Thomas Т.Н.; Laker M.F.; Wilkinson R. // Elevated sodium-lithium countertransport: a familial marker of hyperlipidaemia and hypertension?// J. Hypertens. 1990. - v. 8. - p. 139-146.

152. Catterall W., Epstein P.N. // Ion channels.// Diabetologia. 1992. - v. 35(Suppl 2). - S23-S33.

153. Ceriello A. // Oxidative stress and glycemic regulation.// Metabolism. -2000.-v. 49.-p. 27-29.

154. Ceriello A., Giugliano D., Quatraro A., Donzella C, Dipalo G. and Lefebvre P.J.// Vitamin E Reduction of Protein Glycosylation in Diabetes.// Diabetes Care. 1991. - v. 14. - p. 68-72.

155. Chakrabarti S and Sima AA. // Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in BB rats. //Diabetes. 1989. - v. 38.-p. 1181-1186.

156. Chakravarthy U, Hayes R, Stitt A, McAuley E, Archer D.// Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end-products. //Diabetes.-1998.-v. 47.-p. 945-952.

157. Chance B, Sies H, Boveris A. // Hydroperoxide metabolism in mammalian organs. //Physiol Rev. 1979. - v. 59. — p. 527-605.

158. Chandel NS, Trzyna WC, McClintock DS, Schumacker PT// Role of oxidants in NF-кВ activation and TNF-л gene transcription induced by hypoxia and endotoxin. //J Immunol. 2000. — v. 165. - p. 1013—1021.

159. Chang L., Xu J, Yu F, Zhao J, Tang X, Tang C. // Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats.// Amino Acids. 2004. - v. 27. - p. 37-48.

160. Chen G, Liu P, Thurmond DC, Elmendorf JS// Glucosamine-induced insulin resistance is coupled to O-linked glycosylation of Muncl8c.// FEBS Lett. 2003. - v. 534. - p. 54-60.

161. Chen L.Y., Mehta P., Mehta J.I.// Oxidised LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets.//Circulation. 1996. - v. 93. - p. 1740 - 1746.

162. Chen R., Kim O., Yang J., Sato K., Eisenmann К. M., McCarthy J., Chen H.//Regulation of Akt/PKB activation by tyrosine phosphorilation.// J. Biol. Chem. 2001.-v. 276.-p. 31858-31862.

163. Cheng C, Chang H. //Metabolism of metformin in the rat Abstract. //Drug Metab Rev. 2000. v. 32 (suppl. 2), 266.

164. Chou C, Cheng C, Chang H. //Metabolism of metformin in the rat Abstract. //Drug Metab Rev. 2000. - v. 32 (suppl. 2). -p. 266.

165. Choudhary D., Chandra D., Kale RK. // Influence of on antioxidant enzymes and oxidative damage.// Toxicol. Lett. 1997. — v. 93. — p. 141-152.

166. Chua CC, Hamdy RC, Chua BH// Upregulation of vascular endothelial growth factor by H202 in rat heart endothelial cells. // Free Radic Biol Med. -1998.-v. 25. p. 891-897.

167. Cinar MG, Ulker S, Alper G, Evinc A.// Effect of Dietary Vitamin E Supplementation on Vascular Reactivity on Thoracic Aorta in Streptozotocin-Diabetic Rats. // Pharmacology. 2001. - v. 62. - p. 56-64.

168. Cohen B, Novick D, Rubinstein M // Modulation of insulin activities by leptin.//Science. 1996.-v. 274.-p. 1185-1188.

169. Cohen P. // Dissection of protein kinase cascades that mediate cellular response to cytokines and cellular stress. //Adv Pharmacol. 1996. — v. 36. -p. 15-27.

170. Colaco C.A.L.S., Roser B.J. // BioEssays. 1994. - v.16. - p.145-147.

171. Cominacini L, Pasini AF, Garbin U, Davoli A, Rigoni A// E-Selectin plasma concentration is influenced by glycemic control in NIDDM patients: possible role of oxidative stress.// Diabetologia. 1997. - v.40. - p. 584-589.

172. Consentino F, Hishikawa K, Katusic ZS, Luscher TF// High glucose increases nitric oxide syntase expression and superoxide anion generation in human aortic endothelial cells. // Circulation. 1997. — v. 96. — p. 25-28.

173. Cook N.C. and S. Samman.//Flavonoids: chemistry, metabolism, cardioprotective effects and dietary sources.// J. Nutr. Biochem. — 1996. — v.7. p. 66-76.

174. Coppola L, D'Onofrio F.//L-Arginine for testing endothelium-dependent vascular functions in health and disease.// Am J Physiol. 1997. — v.273. -E606-E612.

175. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL// Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction.// Diabetes. 1992. — v. 41. - p. 552-556.

176. Craven PA, Studer RK, DeRubertis FR //Impaired nitric oxide release by glomeruli from diabetic rats. ///Metabolism. 1995. — v. 44. - p. 695-698.

177. Crouch, R; Kimsey, G.; Priest, D. G.; Sarda, A.; Buse, M. G. // Effect of streptozotocin on erythrocyte and retinal superoxide dismutase. //Diabetologia. 1978. - v. 15. - p. 53-57.

178. Cunningham, JJ. //Micronutrients as Nutriceutical Interventions in Diabetes Mellitus. // J. Am. Coll. Nutr. 1998. - v. 17. - p.7-10.

179. Dawson Т., Bredt D., Fotuni H. //Nitric oxide synthase and neuronal NADFHdiaphorase are identical in brain and peripheral tissues. //Proc. Natl. Acad. Sci USA. 1991. -v.88.- p. 7797-7801.

180. DCCT Research Group. //Diabetes Care. - 1996. - v. 19. p. 195-203.

181. DeFronzo RA// Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. //Diabetes Rev. 1997. — v. 5. -p. 177-269.

182. DeFronzo RA. // Lilly lecture.The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.//Diabetes. 1987. - v. 37. - p. 667687.

183. DeFronzo RA., Tobin JD., Anders R. // Glucose clamp technique: a method for quantifying insulin secretion and resistance.// Am. J. Physiol. -1979.-v.237. -E214-E223

184. DeLong MJ // Apoptosis: a modulator of cellular homeostasis and disease states. //Ann N YAcad Sci. 1998. - v. 842. - p. 82-90.

185. Denikola A. Et al. //Diffusion of peroxinitrite across erythrocyte membranes. //Proc. Natl. Acad. Sci USA. 1998. - v. 95. - p. 3566-3571.

186. Denu JM, Tanner KG//Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation.// Biochemistry. 1998. — v. 37.-p. 5633-5642.

187. Devamanoharan PS, Ali AH, Varma SD.// Prevention of lens protein glycation by taurine.// Mol Cell Biochem. 1997. - v. 177. - p. 245-250.

188. Devaraj S. and Jialal I. // Low-Density Lipoprotein Postsecretory Modification, Monocyte Function and Circulating Adhesion Molecules in Type 2 Diabetic Patients with and without Macrovascular Complications.

189. The Effect of Alpha-Tocopherol Supplementation. //Circulation. 2000. - v. 102.-p. 191-196.

190. Di Donato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M // A cytokine-responsive ЫЗ kinase that activates the transcription factor NF-«B. //Nature. 1997. - v. 388. - p. 548-554.

191. Di Marino L. //Is the erythrocyte membrane fatty acid composition a valid index of skeletal muscle membrane fatty acid composition? //Metabolism. -2000.-v. 49.-p. 1164-1166.

192. Dittmar S., Polanowska-Grabowska R., Gear AR.//Platelet adhesion to collagen under flow conditions in diabetes mellitus. //Thromb. Res. 1994. -v. 74.-p. 273-83.

193. Donati G., Pournaras C. //Decreased Nitric Oxide production accounts for secondary arteriolan constriction after retinal branch vein occlusion.// Invest. Ophthalmol.Visual Sci. 1997. - v. 38. - p. 1450-1457.

194. Donati G., Pournaras C. //Endogenous deficiency of Nitric Oxide is an aggravating factor in retinal vein occlusion.// Klin. Mohatsbl. Augenheilka. -1998. v. 212.-p. 324-335.

195. Donati G., Pournaras C. // Effect of nitroprusside on arteriolar constriction after retinal branch vein occlusion.// Invest. Ophthalmol.Visual Sci. 1998. — v. 39.-p. 1910-1917.

196. Drexler H., Hablawetz E., Lu W., Riede U., Christes A. //Effects of nitric oxide formation on regional blood flow in experimental myocardial infarction.// Circulation. Vol. 1992. - v. 86. -N. l.-P. 255-262.

197. Droge W. //Free radicals in the physiological control of cell function. //Physiol Rev. 2002. - v. 82. - p. 47-95.

198. Du, X., et al. //Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates threemajor pathways of hyperglycemic damage in endothelial cells.//J. Clin. Invest. 2003. - v. 112. - p. 1049-1057.

199. Ducala R., Trasey K.J., Cerami A. //Advanced Glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. // J Clin Invest. 1991. — v.87. - p.432-38.

200. Dunn JA, Patrick JS, Thorpe SR, et al.// Oxidation of glycated proteins: Age-dependent accumulation of N-epsilon-(carboxymethyl) lysine in lens protein. //Biochemistry. 1989. - v. 28. - p. 9464-9468.

201. Dwight J.F.; Hendry B.M. // Effects of membrane incorporation of short-chain phospholipids on sodium pump function in human erthrocytes. //Clin. Chim. Acta. 1995.-v.243.-p. 73-85.

202. Ebina Y., Edery M., Ellis L., Beaudoin J., Roth R. A. // Expression of a functional human insulin receptor from a cloned cDNA in Chinese hamster ovary cells.//Proc Nat Acad SciUSA. 1985.-v. 82.-p. 8014-8018.

203. Esterbauer H., Schaur R.J., Zollner H. // Mechanism of free radical oxidation of unsaturated lipids //Free Radic. Biol. Med. 1991. - v. 11. - p 81-128.

204. Evans JL, Goldfine ED, Maddux BA, Grodsky GM.// Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2.// Diabetes Endocrine Reviews. 2002. — v. 23. — p. 599-622.

205. Evans JL, Jallal B. // Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. //Expert Opin Investig Drugs. 1999. — v. 8.-p. 139-160.

206. Evans JL, Heymann С J, Goldfine ID, Gavin LA // Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled release formulation of a-lipoic acid. //Endocr Pract. 2002. - v. 8. - p. 29-35.

207. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. //Are Oxidative Stress-Activated Signaling Pathways Mediators of Insulin Resistance and (3-Cell Dysfunction? //Diabetes. 2003. - v. 52. - p. 1-8.

208. Ewing F.M.E., Deary Ian J. // Seeing beyond Retinopathy in Diabetes:Electrophysiological and Psychophysical Abnormalities and Alterations in Vision. //Endocrine reviews. 1998. — v. 19. — p. 462 - 476.

209. Farese RV. // Protein kinase C. //In Diabetes Mellitus. A Fundamental and Clinical Text. Ed. By LeRoith D., Taylor SI, Olefsky JM. - Philadelphia. New York: Lippincott-Raven. - 1996. - p. 187-197.

210. Felber J.P., Ferrannini E., Golay A. //Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. //Diabetes. -1987. -v. 36. -p. 1341-1350.

211. Fliegel L.; Murtazina R.; Dibrov P.; Harris C.; Moor A. // Fernandez Rachubinski F.A. Regulation and characterization of the Na+/H+ exchanger.// Biochem. Cell. Biol. 1998. - v.76. - p. 735-741.

212. Fore W.W.//Noninsulin-dependent diabetes mellitus. The prevention of complications. // Med. Clin. North Am.- 1995. v.79.- n. 2.- p. 287-298.

213. Froguel P, Velho G//Genetic determinants of type 2 diabetes. //Recent ProgHormRes. 2001.-v. 56.-p. 91-105.

214. Frost SC, Lane MD// Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes.// J Biol Chem. 1985. - v. 260. - p. 2646-2652.

215. Fu MX, Knecht KJ, Thorpe SR, Baynes JW. Role of oxygen in crosslinking and chemical modification of collagen by glucose. //Diabetes, 1992. v. 41(Suppl 2). - S.42-48.

216. Fuller C.J.; Agil A.; Lender D. //Superoxide production and LDL oxidation by diabetic neutrophils. //J. Diab. Compl. 1996. - v. 10- p. 206-210.

217. Gaede P, Poulsen HE, Parving HH, Pedersen O.// Double-Blind, Randomized Study of the Effect of Combined Treatment with Vitamin С and E on Albuminuria in Type 2 Diabetic Patients.//Diab. Med 2001. - v. 18. - p. 756-760.

218. Garber A.J. //Vascular disease and lipids in diabetes. // Med. Clin. North Am. 1998. - v.82. - n. 4.- p.931-948.

219. Garg A. // Dyslipoproteinemia and diabetes. // Endocrinol. Metab. Clin. North Am. 1998. - v.27. - N3. - p.613-625.

220. Garg A.//Treatment of diabetic dyslipidemia. // Am. J. Cardiol. 1998. -v. 81: 47B-51B.

221. Geps W, Lecompe P //The pancreatic islets in diabetes. //Am J. Med -1981. -v.70. -p. 105-114

222. Giardino I, Edelstein D, Brownlee M. // BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. //J Clin Inv. 1996. - v.91. — p.1422-1428

223. Gille G., Sigler K.// Oxidative stress and living cells.// Folia Microbiol. 1995.- v. 40. p. 131-152.

224. Gisinger C, Jeremy J, Speiser P, Mikhailidis D, Dandona P//Effect of vitfmin E supplementation on platelet thromboxane A2 production in type 1 diabetic patients.// Diabetes. 1988. - v. 37. - p. 1260-1264.

225. Giugliano D., Ceriello A., Paolisso G.//Oxidative stress and diabetic vascular complications.// Diabetes Care. 1996. - v. 19. — p. 257-267.

226. Grisham MB, Jefferson M, Melton DF. //Chlorination of endogenous amines by isolated neutrophils.//J Biol Chem. 1984. - v.259. - p. 10404-10413.

227. Golay A., Zech L., Shi M.Z.// High density lipoprotein (HDL) metabolism in non-insulin dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL.//J.Clin. Endocrinol. Metab. 1987. - v.65. - p. 512-518.

228. Goldstein BJ. // Protein-tyrosine phosphatase IB (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity, and related states of insulin resistance. //Curr Drug Targets. 2001. — v.l. — p. 265—275.

229. Goldstein BJ, Ahmad F, Ding W, Li PM, Zhang WR// Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. //Mol Cell Biochem. 1998. - v. 182. - p. 91-99.

230. Gores GJ, Herman B, Lemasters JJ //Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury .//Hepatology. 1990.-v.l 1. -p. 690-698.

231. Gorogawa S, Kajimoto Y, Umayahara Y et al.// Probucol preserves pancreanic P-cell function through reduction of oxidative stress in type 2 diabetes//Diabetes Res Clin Pract. 2002. - v. 57. - p. 1-10.

232. Grankvist K, Marklund S, Taljedal IB. //Superoxide dismutase is a prophylactic against alloxan diabetes.//Nature 1981. - v. 294. - p.158 —160

233. Grankvist K, Marklund SL, Taljedal IB// CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. //Biochem J. 1981. — v. 199. - p. 393-8.

234. Gremlich S, Bonny C, Waeber G, Thorens B// Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels.// J Biol Chem. 1997. - v. 272. - p. 30261-30269.

235. Grinstein S., Rotin D., Mason M.J. /ЛЧа+/ЕГ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. // Biochim. Biophys. Acta. 1989. - v. 988. - p. 73-97.

236. Grisham MB, Jefferson M, Melton DF, Thomas EL. // Chlorination of endogenous amines by isolated neutrophils. //J Biol Chem. 1984. — v.259. p. 10404-10413.

237. Grunfeld C, Feingold ICR. //The metabolic effects of tumor necrosis factor and other cytokines.// Biotherapy. 1991. — v. 3. — p.143-158.

238. Guiot Y, Sempoux C, Moulin P //No decrease of the beta-cell mass in type 2 diabetic patients.//Diabetes. 2001. - v. 50(Suppl 1). - SI88.

239. Haefliger IO, Flammer J, Ltischer TF. // Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery.// Invest Ophthalmol Vis Sci. 1997. - p. 33. - p. 2340-2343.

240. Hampton MB, Orrenius S//Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. //FEBS Lett. 1997. - v. 414.-p. 552-556.

241. Hanefeld M., Schmechel H., et al. // Determinants for coronary heart disease in non-insulin-dependent diabetes mellitus: lessons from the diabetes intervention study//Diabetes Res Clin Pract.- 1996. v. 30 (suppl.) - p.67-70.

242. Hannan K.M.; Little P.J.//Mechanisms regulating the vascular smooth muscle Na/H exchanger (NHE-1) in diabetes.// Biochem. Cell Biol. 1998 -v.76. - p. 751-759.

243. Hansford RG, Hogue BA, Mildaziene V //Dependence of H202 formation by rat heart mitochondria on substrate availability and donor age.// J Bioenerg Biomembr. 1997. - v. 29. - p. 89-95.

244. Haraguchi H., Ohmi I. et al. //Ingibition of aldose reductase and sorbitol accumulation by astilbin and taxifolindigidroflavonols in Engelhardtia chrisolepis.// Biosci. Biotechnol. Biochem. 1996. - v.60. - p. 945-8.

245. Harman D. //The free-radical theory of aging.// Free Radicals in Biol. -1982.-v. 5.-p. 256-275.

246. Harmon JS, Gleason CE, Tanaka Y, et al //In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression.// Diabetes. 1999. -v. 48. - p. 1995 -2000.

247. Harmon JS, Tanaka Y, Olson LK, Robertson RP//Reconstitution of glucotoxic ШТ-Т15 cells with somatostatin transcription factor-1 partially restores insulin promoter activity. //Diabetes. 1998. - v. 47. - p. 900 —904.

248. Harrison D.//Cellular and Molecular Mechanisms of Endothelial Cell Dysfunction.// J.Clin. Invest. 1997. - v. 100. - p. 2153-2157.

249. Hart GW. // Dynamic O-linked glycosylation of nuclear and cytoskeletalrproteins. //Ann Rev. Biochem. 1997. - v. 66. - p. 315-335.

250. Hazav P., Shany S., Moran A., Levy R. //Involvement of intracellular pH elevation in the effect of 1, 25-dihydroxyvitamin D3 on HL 60 cells. // Cancer Res. 1989. - v. 49. - p. 72-75.

251. Head K.A. // Natural therapies for ocular disoders, part two: cataracts and glaucoma. //Altern. Med. Rev. 2001. - v.6. - p. 141-166.

252. Heemskerk J. W. M., Sage S. O. // Calcium signalling in platelets and other cells. //Platelets. 1994. - v. 5. - p. 295-316.

253. Heffetz D, Bushkin I, Dror R, Zick Y// The insulinomimetic agents H202 and vanadate stimulate protein tyrosine phosphorylation in intact cells. //J Biol Chem. 1990. - v. 265. - p. 2896-2902.

254. Helge J.W.; Kriketos A.D.; Storlien L.H. // Insulin sensitivity, muscle fibre types, and membrane lipids.//Adv. Exp. Med. Biol. 1998. — v. 441. — p. 129-138.

255. Hempel A, Maasch C, Heintze U et al.// High glucose concentrations increase endothelial cell permeability via activation of protein kinase C-a. // CircRes. 1997.-v.81.-p. 363-371.

256. Henriksen EJ, Holloszy JO//Effects of phenylarsine oxide on stimulation of glucose transport in rat skeletal muscle.//Am J Physiol. 1990;- v.258. -C648-C653.

257. Hicks M, Delbridge L, Yue DK, et al// Catalysis of lipid peroxidation by glucose and glycosylated collagen. //Biochem Biophys Res Commun. 1988. -v.151. -p.649-655.

258. Hicks M, Delbridge L, Yue, DK, et al. //Increase in crosslinking of nonen-zymatically glycosylated collagen induced by products of lipid peroxidation. //Arch Biochem Biophys. 1989. - v.268. - p. 249-254.

259. Hirai N, Kawano H, Hirashima O, Motoyama T, Moriyama Y, Sakamoto T, Kugiyama K, Ogawa H, Nakao K, Yasue H // Insulin resistance andendothelial dysfunction in smokers: effects of vitamin C. // Am J Physiol. -2000. v. 279. - p. HI 172-H1178.

260. Hiramatsu K., Nozaki H., Arimori-S. // Studies on platelets in diabetic patients. Part 2: Compositional changes of lipid in hyperaggregation platelets.// Clin. Haematol. 1981. - v.22. - p. 849-854.

261. Hirose H, Lee YH, Inman LR, Nagasawa Y, Johnson JH, Unger RH// Defective fatty acid-mediated B-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes.// J Biol Chem. -1996. v.271. - p. 5633-5637.

262. Ho E, Chen G, Bray ТМУ/ Supplementation of N-acetylcysteine inhibits NF-kappaB activation and protects against alloxan-induced diabetes in CD-I mice. //FASEB J. 1999.-v. 13.-p. 1845-1854.

263. Ho E, Bray ТМУ/ Antioxidants, NF-kappaB activation, and diabetogenesis. //Proc Soc Exp Biol Med.- 1999. v. 222. - p. 205-213.

264. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. // Inhibition of low-density lipoprotein oxidation by nitric oxide.// FEBS letts. 1993.-v. 334.-p. 170-174.

265. Hollenbeck C, Reaven GM// Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance.// J Clin Endocrinol Metab. 1987. -v. 64. - p. 1169-1173.

266. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M. //Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. //Arterioscler Thromb Vase Biol. 2000. - v. 20. - p. 15951599.

267. Hotta N. // New approaches for treatment in diabetes: aldose reductase inhibitors.// Biomed. Pharmacother. 1995. - v.49. - p. 232-243.

268. Hovind P, Tarnow L, Oestergaard PB, Parving HH Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. //Kidney Int. 2000. - v. 57(Suppl 75). - S56-S61.

269. Howard B.V. Insulin resistance and lipid metabolism. // Am. J. Cardiol. -1999-v. 84.-p. 28J-32J.

270. Howard B.V., Howard W.J. //Dyslipidemia in Non-Insulin-Dependent Diabetes Mellitus. //Endocr. Rev. 1994. - v.15.- n3.- p. 263-275.

271. Hsu Ch, Huang Ch, Hung Y, Yin M. //Five cysteine-containing compounds have antioxidant activity in Balb/cA mice.// J Nutr. 2004. - v. 134.-p.149-152.

272. Hsueh WA, Law RE// Cardiovascular risk continuum: Implications of insulin resistance and diabetes. //Am J Med. 1998. - v. 105. - 4S-14S.

273. Hunt JV, Bottoms MA, Clare K, et al.//Glucose oxidation and low-density lipoprotein-induced macrophage ceroid accumulation: possible implications for diabetic atherosclerosis./ZBiochem J. 1994. - v.300. - p. 243-249.

274. Hunt JV, Smith CCT, Wolff SP// Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. //Diabetes. 1990. - v. 39. - p. 1420-1424.

275. Hunter T //The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease.// Philos Trans R Soc Lond В Biol Sci. 1998. - v. 353. - p. 583-605.

276. Ido Y., Kilo C., Williamson J.R. //Cytosolic NADH/NAD+, free radicals, and vascular disfunction in early diabetes mellitus. //Diabetologia. 1997. -v.40(Suppl 2). - S115-S117.

277. Idris I., Gray S., Donnelly R. // Protein kinase С activation: isozyme-specific effects on metabolism and cardiovascular cjmplications in diabetes.// Diabetologia.- 2001. v.44. - p. 659-673.

278. Ihara Y, Yamada Y, Toyokuni S, Miyawaki K, Ban N, Adachi T, Kuroe A, Iwakura T, Kubota A, Hiai H, Seino Y.// Antioxidant alpha-tocopherolameliorates glycemic control of GK RATS, a model of type 2 diabetes. //FEBS~Lett.- 2000. v.473. - p. 24-26.

279. Insel P., Hirenberg P., Turubull J., Shattil S. //Biochemistry. 1978. -v.17.-p. 24.

280. Ishii H., Daisuke K., King G.L.//Protein kinase С activation and it's role in the development of vascular complications in diabetes mellitus.// J. Mol.Med. 1998.-v. 76. - p. 21-31.

281. Ishii H., Umeda P., Nawata H. //Platelet function in diabetes mellitus.// Diabetes/Metab. Rev. 1992. - v.8. - p. 53-66.

282. Jackson R.L., Gotto A.M. // Phospholipids in biology and medicine. //New Engl. J. Med. 1974. - v. 3. - p. 24-29.

283. Jacob S, Henriksen EJ, Schiemann AL, Simon I,Clancy DE, Tritschler HJ, Jung WI, Augustin HJ, Dietze GJ.// Enhancement of glucose disposal in patient wit type 2 diabetes by alpha-lipoic acid. //Arzneim.-Fordch. 1995. -v. 45.-p. 872-874.

284. Jacob S, Lehmann R, Rett К, Ha. ring H-U// Oxidative stress and insulin action: a role for antioxidants.// In Antioxidants in Diabetes Management. -Packer L, Ro. sen P, Tritschler HJ, King GL, Eds. New York, Marcel Dekker. - 2000. p. 319-338.

285. Jacobsen J.G., Smith L. H. // Biochemistry and physiology of taurine and taurine derivates. //Physiol Rev. 1968. - v.48. - p. 424-511.

286. Jaeschke H. // Mechanisms of oxidant stress-induced acute tissue injury.//Proc. Soc. Exp. Biol. And Med. 1995. - v. 209. - p. 104-111.

287. Jain R. S., Vyas C. R. // Garlic in alloxan-induced diabetic rabbits. // Am. J. Clin. Nutr. 1975. - v. 28. - p. 684-685.

288. Jain R. S., Vyas C. R. // Hypoglycaemia action of onion on rabbits. // Br. Med. J. 1974. - v.52. - p.730.

289. Jain S.K., McVie R. and Smith T. //Vitamin E Supplementation Restores Glutathione and Malondialdehyde to Normal Concentrations in Erythrocytes of Type 1 Diabetic Children.//Diabetes Care. 2000. - v.23. - p.1389-1394.

290. Jain S.K., McVie R., Duett J., Herbst J.J.// Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes.// Diabetes. 1989. — v.38.-p. 1539-1543.

291. Jain SK, Mc Vie R, Jaramillo JJ, Pakmer M, Smith T, Meachum ZD, Little RL//The effect of modest vitamin E supplementation on lipidperoxidation products and other cardiovascular risk factors in diabetic patients.//Lipids. 1996. - v. 31. - S87-S90.

292. Jiang ZY, Woollard AC, Wolff SP. // Hydrogen peroxide production during experimental protein glycation.// FEBS Lett. 1990. — v. 268. — p. 6971.

293. Jandeleit-Dahm K., Hannan K., Farrelly C. // Diabetes- induced vascular hypertrophy is accompanied by activation of Na/H exchange and prevented by Na/H exchange inhibition.// Circ. Res. 2000. - v. 87. - p. 1133-1140.

294. Jones DB., Davis TM., Bown E., Carter RD., Mann JL, Prescott RJ. // Determinants of ADP-induced platelet aggregation in diabetes mellitus.// Diabetologia. 1986. - v. 29. - p. 291-294.

295. Kahn CR //Insulin action, diabetogenes, and the cause of type II diabetes. //Diabetes. 1994. - v. 43. - p. 1066-1084.

296. Kahn CR, Vicent D, Doria A // Genetics of non-insulin-dependent (type-II) diabetes mellitus.//Annu. Rev. Med. 1996. - v. 47. - p. 509-531.

297. Kajimoto Y, Matsuoka T, Kaneto H, Fujitani Y, Kishimoto M, Sakamoto K, Matsuhisa M, Kawamori R, Yamasaki Y, Hori M//Induction of glycation suppresses glucokinase gene expression in ШТ-Т15 cells. // Diabetologia. -1999.-v.42.-p. 1417-1424.

298. Kalofoutis A., Lekakis J. //Changes of platelet phospholipids in diabetes mellitus. //Diabelologia. 1981.-v. 21.-p. 540-543.

299. Kannel W.B., McGee D.L. //JAMA . 1979. - v. 241. - p. 2035-2038.

300. Karpen CW., Cataland S., O'Dorisio TM., Panganamala R. // Intervention of platelet vitamin E and thromboxane synthesis in type 1 diabetes mellitus. // Diabetes. 1984. - v. 33. - p. 239-43.

301. Kasuga M., Karlsson F.A., Kahn C. R. // Insulin stimulates and phosphorylation of the 95.000 dalton (3- subunit of its own receptor. // Science. 1983.-v. 215.-p. 185-187.

302. Kato H., Shin D., Hayase F. //3-deoxyglucosone crosslinks proteins under physiologic conditions.// Agric. Biol. Chem. 1987. - v. 51. - p. 2009-2011.

303. Kaul N., Siveski-Iliskovic N., Hill M. et al. // Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. // Mol. Cell. Biochem. 1996. - v. 160. - p. 283-288.

304. Kaul N., Siveski-Iliskovic N., Thomas T.P. et al.// Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. //Nutrition. 1995. — v. 11. — p. 551-554.

305. Kawamura M, Heinecke JW, Chait A.//Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway.// J Clin Invest. 1994. — v. 94. p. 771-778.

306. Keenoy M. // The effect of flavonoid treatment on the glycation and antioxidant status in type 1 diabetic patients. // Diabetes Nutr. Metab.- 1999. v.l2.-n. 4.-p. 256-263.

307. Kerr JF, Wyllie AH, Cunie AR// Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. // Br J Cancer. 1972. — v. 26.-p. 239-257.

308. Keyse SM//The role of protein phosphatases in the regulation of mitogen and stress-activated protein kinases. //Free Radic Res. 1999. — v.31 — p. 341-349.

309. Keyse SM Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. //Curr Opin Cell Biol. 2000. — v. 12 - p. 186-192.

310. Khoo S, Cobb MH //Activation of mitogen-activating protein kinase by glucose is not required for insulin secretion.// Proc Natl Acad Sci USA. -1997.-v. 94.-p. 5599-5604.

311. Kido Y, Nakae J, Accili D //Clinical review 125: the insulin receptor and its cellular targets. // J Clin Endocrinol Metab. 2001. - v. 86. - p. 972-979.

312. Kilo C, Volger N, Williamson JR. //Muscle capillary basement membrane changes related to aging and to diabetes mellitus.// Diabetes. 1972. - v. 21. -p. 881-905.

313. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GUI Prevention of fat-induced insulin resistance by salicylate.// J Clin Invest. 2001. - v. 108. - p. 437-446.

314. King GL, Brownlee M //The cellular and molecular mechanisms of diabetic complications .//Endocrinol Metab Clin North Am. 1996. v. 25. -255-270.

315. King, H., Aubert, R.E. and Herman.W.H.// Global Burden of Diabetes, 1995-2025. Prevalence, Numerical Estimates and Projections. //Diabetes Care.- 1998.- v. 21.-p. 1414-1431.

316. Kirstein M, Aston C, Hintz R, Vlassara H.// Receptor-specific inductionof insulin-like growth factor I in human monocytes byadvanced glycosylation end product-modified proteins. //J Clinlnvest. -1992. — v. 90. p. 439-446.

317. Klein R, Klein BE, Moss SE, et al. //The Wisconsin epidemiologic study of diabetic retinopathy XIV: Ten year incidence and progression of diabetic retinopathy.// Arch Ophthalmol. 1994. - v.l 12. - p. 1217-1228.

318. Klein R, Klein BE, Moss SE, et al. //The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. // Ophthalmology. 1995. - v.102. - p. 7-16.

319. Kloppel G, Lohr M. Habich K, Oberholzer M //Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited.// Survey and Synthesis of Pathology Research. — 1985. — v.4 p. 110-125.

320. Knott H.M., Brown E.B., Davies M.J., Dean R.T.//Glycation and glycoxidation of low-density lipoproteins by glucose and low molecular mass aldehydes: Formation of modified and oxidized particles // Eur.J.Biochem.-2003. v.270. - p. 3572-3582.

321. Knowles J.//Enzyme catalysis: not different, jast better. //Nature. 1991. -v. 350. —p. 121-124.

322. Kohn HI, Liverstdge M. //On new aerobic metabolite whose production by brain is inhibited by apomorphine, emetine, ergotamine, epinephrine and menadione. //J. Pharmacol. Exptl. Ther. 1944. - v.82. - p. 292-300.

323. Koren W.; Koldanov R.; Pronin V.S. et al.// Amiloride-sensitive Na+/H+ exchange in erythrocytes of patients with NIDDM: a prospective study. // Diabetologia. 1997. - v. 40. - p. 302-306.

324. Koya D, King GL// Protein kinase С activation and the development of diabetic complications. //Diabetes. 1998. - v.47. - p. 859-866.

325. Koya D, Lee IK, Ishii H, Kanoh H, King GL //Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol.// J Am Soc Nephrol. 1997. - v. 8. - p. 426-435.

326. Kozawa O, Kawamura H, Hatakeyama D, Matsuno H, Uematsu T//

327. Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts involvement of p38 mitogen-activated protein kinase.// Cell Signal. 2000. - v. 12. - p. 375-380.

328. Krajewska E.; Zavodnik I.; Kluska В.; Szosland K.; Bryszewska M. // Acetylcholinesterase activity of normal and diabetic human erythrocyte membranes: the effect of oxidative agents.// Biochem. Mol. Biol. Int. 1997. -v.42.-p. 203-210.

329. Krolewsky A. S., Warram J. H., Valsania P., Martin В. C., Laffel L. M., Christlieb A.// Evolving natural history of coronary artery disease in diabetes mellitus.// Am. J. Med. 1991. - v. 90. - 56S-61S.

330. Kruse-Jarres J. D., Jaraush J., Lehmann P., Vogt B. W. and Riets P. //A new colorimetric method for determination of fructozamine.// Lab. Med. -1989.- v. 13.-p. 245-250.

331. Kuehl FA, Egan RW. // Prostaglandins, arachidonic acid and inflammation. //Science. 1980.-v. 210.-p. 978-84.

332. Kumamoto T, Kuvabaro DG. //Influence of intensive glucose controle on diabetic retinopathy in NIDDM. //Arch Ophthalmol. 1990. - v. 69. - p.492.

333. Kuusisto J., Mykkanen L.//NIDDM and its metabolic control predict coronary heart disease in elderly subjects.// Diabetes. 1994. — v.43. — p.960.967.

334. Kyriakis JM, Avruch J//Sounding the alarm: protein kinase cascades activated by stress and inflammation.// J Biol Chem. 1996. — v.271. — p. 24313-24316.

335. Lai MA, Korner A, Matsuo Y. et al. // Combined antioxidant and COMT inhibitor treatment reverses renal abnormal ities in diabetic rats. // Diabetes. 2000. - v. 49. - p. 1381-1389.

336. Laight D.W., Carrier M.J., Anggard E. E. // Cardiovasc. Res. 2000. - v. 47.-p. 457-464.

337. Lai S., Szwergold B.S., Taylor A.//Metabolism of fructose-3-phosphate in the Diabetic Rat Lens//Arch. Biochem. Biophys. 1995. - v.318. - p. 191-9.

338. Lameloise N, Muzzin P, Prentki МУ/ Assimacopoulos-Jeannet F Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? //Diabetes. 2001 — v. 50. - p. 803-809.

339. Lampson W. G., Kramer J. H., Schaffer S. W. // Potentiation of the actions of insulin by taurine.//Can J Physiol Pharmacol. -1983. p. 61. — p.457- 463.

340. Lankin V. // In: "Free Radicals, Nitric Oxide, and Inflammation: Molecular, Biochemical, and Clinical Aspects. // Amsterdam etc.: IOS Press, NATO Science Series. 2003. - vol. 344. - p. 8-23.

341. Lankin V., Tikhaze A. //In: In: "Free Radicals, Nitric Oxide, and Inflammation: Molecular, Biochemical, and Clinical Aspects.// Amsterdam etc.: IOS Press, , NATO Science Series. 2003. - vol.344, -p. 218-231.

342. Larkins R.G., Dunlop M.E. //The link between hypergcaemia and diabetic nephropathy. //Diabetologia. 1992. - v.35. - p. 499-504.

343. Lavan BE, Lane WS, Lienhard GE// The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. //J Biol Chem. 1997. - v. 272. - p. 11439-11443.

344. Le Good J. A., Zeigler W. H., Parekh D. В., Alessi D. R.,et al// Protein kinase С isotypes controlled by phosphoinositide-3-kinasethrough the protein kinase PDK1.//Science. 1998. - v. 281. - p. 2042-2045.

345. Le Marchand-Brustel Y, Gremeaux T, Ballotti R, et al// Insulin receptor tyrosine kinase: is defective in skeletal muscle of insulin-resistant obese mice.// Nature. 1985. - v. 315. - p. 676-679.

346. Lee AY, Chung SS// Contributions of polyol pathway to oxidative stress in diabetic cataract. //FASEB J. 1999. - v. 13. - p. 23-30.

347. Lebovitz H. Т., Melander A .// Sulfonylureas: Basic Aspects and clinical uses.// in International Textbook of Diabetes Mellitus. Edited by M. Alberti, R.A. De Fronzo, H. Keen and P. Zimmet @John Wiley(Sons Ltd )- 1992. -pp 746-772.

348. Leibowitz G, Yuli M, Donath MY, Nesher R, Melloul D, Cerasi E, Gross DJ, Kaiser N B-Cell glucotoxicity in the Psammomys obesus model of type 2diabetes. Diabetes. 2001. - v. 50 (Suppl 1). - S113-S117.

349. Li D, Devaraj S, Fuller C, Bucala R, Jialal I// Effect of a-Tocopherol on LDL oxidation and glycation: in vitro and in vivo studies.// J Lipid Res. -1996.- v.37.-p. 1978-1986.

350. Li H, Li JC, Jiang SS, Du H, Gu XP. //Inhibiting effect of taurine on nonenzymatic glycosylation of aortic collagen in diabetic rats //Chin Pharmacol Bull. 1996. - v. 12. - p. 445^47.

351. Li J, DeFea K, Roth RA //Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. //J Biol Chem. 1999. - v.274. - p. 9351-9356.

352. Li J, Schmidt AM. // Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.// J Biol Chem. 1997.-v.272.-p. 16498-16506.

353. Li P-F, Maasch C, Haller H, Dietz R, von Harsdorf R//Requirement for protein kinase С in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. // Circulation. 1999. - v. 100. - p. 967-973.

354. Li W, Wang W, Liu X//Comparative study of high-glucose effect on phosphatidylcholine hydrolysis of cultured retinal capillary pericytes and endothelial cells.//Biochim Biophys Acta. 1994. — v. 1222. —p. 339-347.

355. Lin KT, Xue JY, Nomen M, Spur B, Wong PY //Peroxynitrite-induced apoptosis in HL-60 cells. //JBiol Chem. 1995. - v. 270. - p. 16487-16490.

356. Ling L, Cao Z, Goeddel DV. //NF-«B-inducing kinase activates ПСК-а by phosphorylation of Ser-176.//Proc Natl Acad Sci USA. 1998. - v. 95. - p. 3792-3797.

357. Liu X, Wang J, Takeda N, Binaglia L. et al //Changes in cardiac protein kinase С activities and isozymes in streptozotocin-induced diabetes. //Am J Physiol. 1999. - v. 277. - E798-E804.

358. Liu YQ, Tornheim K, Leahy JL.//Shared biochemical properties of gluco-toxicity and lipotoxicity in islets decrease citrate synthase activity and increase phosphofructokinase activity //Diabetes. 1998. - v.47 — p. 1889-93.

359. Livne A; Balfe JW; Veitch R; Marquez Julio A; Grinstein S; Rothstein A.// Increased platelet Na+-II+ exchange rates in essential hypertension: application of a novel test.// Lancet.- 1987. Mar.- p.533-536.

360. Lopes-Virella M.F., Mironova M., Virella G. //LDL-containing immune complexes and atherosclerosis in diabetes. //Diabetes Rev. 1997. — v.5. -p.410-424.

361. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R.// Advanced glycation end products increase retinal vascular endothelial growth factor expression.// J Clin Invest. 1998. - v. 101. - p. 1219-1224.

362. Lucchesi P.A.; Berk B.C.//Regulation of sodium-hydrogen exchange in vascular smooth muscle. // Cardiovasc. Res. 1995. - v. 29. - p. 172-177.

363. Ludvik B, Nolan JJ, Baloga J, Sacks D & Olefsky J. // Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. //Diabetes. 1995. - v. 44. - p. 1121-1125.

364. Lui LS, Spelleken M, Rohrig K, Hauner H. // Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: impli-cation of the p80 tumor necrosis factor receptor. //Diabetes. 1998. - v.47. - p. 515-522.

365. Lyons T.J., Jenkins A.J. // Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonil stress hypothesis. //Diabetes Rev. 1997. - v. 5. - p. 365-391.

366. Lyons T. J., Li W., Wells-Knecht M. C., Jokl R. // Toxicity of midly modified low-density lipoproteins to cultured retinal capillary endotelial cells and pericytes. //Diabetes. 1994. - v.43. - p. 1090-1095.

367. Maclean N & Ogilvie RE//Quantitative estimation of the pancreatic islet tissue in diabetic subjects./ZDiabetes. 1955. - v4. — p.367-376.

368. Maddux BA, See W, Lawrence Jr JC, Goldfine AL, Goldfine ID, Evans JL// Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of о-lipoic acid. //Diabetes. -2001.-v. 50.-p. 404—410.

369. Maechler P, Jornot L, Wollheim CB // Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. // J Biol Chem. 1999. - v. 274. - p. 27905 -27913.

370. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY // Distinct effects of saturated and monounsaturated fatty acids on 13-celI turnover and function.// Diabetes. 2001. - v. 50. - p. 69-76.

371. Maegawa H., ShigetaY., Egawa К., Kobayashi M.// Impaired autophosphorylation of insulin receptors from abdominal skeletal mysclesin nonobese subjects withNIDDM. //Diabetes. 1991. - v. 40.-p. 815-819.

372. Mahadev K, Zilbering A, Zhu L, Goldstein BJ// Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyro sine phosphatase IB in vivo and enhances the early insulin action cascade.// J Biol Chem. 2001.- v. 276.-p. 21938-21942.

373. Mahnensmith R.L., Aronson P.S. //The Plasma membrane sodium-hydrogen exchanger and its role in physiological and pathophysiological processes. Ill Circ. Res. 1985. - v/57. — p. 773.

374. Major CD, Gao ZY, Wolf В A// Activation of the sphingomyelina-se/ceramide signal transduction pathway in insulin-secreting beta-cells: role in cytokine-induced beta-cell death. //Diabetes. 1999. — v. 48. — p. 1372-80.

375. Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG //Determinants of the selective toxicity of alloxan to the pancreatic В cell. // Proc Natl Acad Sci USA.- 1982. v.79. - p. 927 -930.

376. Malamas MS, Sredy J, McCaleb M, Gunawan I, Mihan B, Sullivan D. //Antihyperglycemic activity of new l,2,4-oxadiazolidine-3,5-diones. //Eur J Med Chem. 2001- v. 36. - p. 31-42.

377. Malone J. I., Lowitt S, Cook W. R. //Non-osmotic diabetic cataracts.//Ped Res. 1990. - v. 27. - p. 293- 296.

378. Mandal S., Sarode R., Dash S., Dash RJ//Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsu-lin-dependent diabetes mellitus. //Am J Clin Pathol -1993. v.100 - p. 103- 7.

379. Manzella D, Barbieri M, Ragno E, Paolisso G. //Chronic adminisnration of pharmacologic doses of vitavin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. // Am J Clin Nutr.- 2001.- v. 73:1052-1057.

380. Matkovics B. //Effect of plant and animal tissue lesions on superoxide dismutase activities. // In: Michelson, A. M.; McCord, J. M.; Fridovich, I., eds.- Superoxide and superoxide dismutase. London: Academic Press. — 1977.-pp. 501-515.

381. Matsuda M., De Fronzo R. A.// Insulin sensitivity indiced obtained from oral glucose tolerance testing. //Diabetes Care. 1999. - v.22. — p. 1462-70.

382. Matthews D.,Hosker J., Rudenski A., Naylor В., Treacher D., Turner R.// Homeostasis model assesment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. //Diabetologia. -1985.-v. 28.-p. 412-419.

383. Maturo J., Kulakowsky E. C. // Insulin-like activity of taurine. // In: The biology of taurine: methods and mechanisms. Huxtable R.J., Franconi F., Giotti A. (eds). - Plenum Press, New York. - 1987. - pp-217-226.

384. Mazzanti L., Rabini R A., Faloila E., Fumelli P., Bertoli E., Roberto de Pirro. // Altered cellular Ca and Na transport in diabetes mellitus. //Diabetes. 1990. - v. 39. - p. 850-854.

385. McConkey DJ, Hartzell P, Nicotera P, Wyllie AH, Orrenius S// Stimulation of endogenous endonuclease activity in hepatocytes exposed to oxidative stress.//Toxicol Lett. 1988. - v.42. -p. 123-130.

386. McGarry JD, Dobbins RL// Fatty acids, lipotoxicity and insulin secretion.// Diabetologia. 1999. - v. 42. - p. 128-138.

387. Melov S//Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging.//Ann NY Acad Sci -2000 v. 908 - p. 219-225.

388. Melov S, Coskun P, Patel M, Tuinstra R, Cottrell B, Jun AS, Zastawny TH, et al// Mitochondrial disease in superoxide dismutase 2 mutant mice. //Proc Natl Acad Sci USA. 1999. - v. 96. - p.846-851.

389. Mercurio F, Zhu H, Murray BW, Shevchenko A, et al /ЯКК-1 and IKK-2: cytokine-activated I«B kinases essential for NF-кВ activation. //Science. -1997.-v.278.-p. 860-866.

390. Mi chalk DV, Wingenfeld P, Licht CH.// Protection against cell damage due to hypoxia and reoxygenation: the role of taurine and the involved mechanisms. // Amino Acids. 1997. — v.13. - p. 337—346.

391. Michelson AD., Benoit SE., Furman MI., et al.// Effects of endothelium-derived relaxing factor/nitric oxid on platelet surface glycoproteins. // Am. J. Physic. 1996. - v. 270. - H1640 - H1648.

392. Miyazaki Y, Matsuda M., DeFronzo R. A. // Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes// Diabetes Care. 2002. - v. 25. - p. 517-523.

393. Miwa I, Ichimura N, Sugiura M, Hamada Y, Taniguchi S// Inhibition of glucose-induced insulin secretion by 4-hydroxy-2-nonenal and other lipid peroxidation products.// Endocrinology. 2000. — v. 141. - p.2767—2772.

394. Mizutani M, Kern TS, Lorenzi M. //Accelerated death of retinal microvascular pericytes in human and experimental diabetic retinopathy.//! Clin Invest. 1996. - v. 97. - p. 2883-2890.

395. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP //The role of oxidative stress and NF-кВ activation in late diabetic complications.//Вiofactors. 1999. - v.10. — p. 157-167.

396. Moncada S, Palmer RMJ, Higgs EA.//Nitric oxide: physiology, pathophysiology, and pharmacology .//Pharmacol. Rev.-1991. — v. 43. — p.109-142.

397. Mueller S., Riedel H.D., Stremmel W. // Direct evidence for catalase as the predominant H202 — removing enzyme in human erythrocytes. //Blood. 1997. - v. 90. - No. 12. - pp. 4973-4978.

398. Mugge A., Elwell J.H., Peterson Т.Е. et al. //Release of intact endothelium derived relaxing factor depends on endothelial superoxide dismutase.//Am.J.Physiol. 1991. - v. 260. - C219-C225.

399. Muggleton Elliott et al. //The effects of plant flavonoids on mammalian cells. Implications for inflammation, heart desease and cancer.//Pharmacological reviews. 2000. - v.52. - Issue 4. - p.673-751.

400. Mullarkey CJ, Edelstein D. Brownlee M //Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes.// Biochem Biophys Res Commun. 1990. - v. 173. - p. 932-939.

401. Mtiller G, Ertl J, Gerl M, Preibisch G//Leptin impairs metabolic actions of insulin in isolated rat adipocytes. //J Biol Chem. 1997. —v. 272. — p. 1058510593.

402. Nadler J, Winer L. //Free radicals, nitric oxide and diabetic complications. // In Diabetes Mellitus. LeRoith D, Taylor SI, Olefsky M (eds). -Lippincott-Raven: Philadelphia. - 1996. - p. 840-848.

403. Nagpala PG, Malik A, Vuong PT, Lum H. // Protein kinase C-pi overexpression augments phorbol ester-induced increase in endothelial permeability. //J Cell Physiol. 1996. - v.166. - p.249-255.

404. Nakashima S., Tohmatsu T. et al. //Inhibitory action of cGMP on secretion, phosphoinositide hydrolysis and calcium mobilization intrombin stimulated human platelets. // Biochim Biophys Res Commun. -1986. -v.135.-p. 1099-1104.

405. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J// Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. //Am J Physiol. 1997. - v.273. - H2224-H2231.

406. Newton AC// Protein kinase C: structure, function and regulation; minireview. // J Biol Chem. 1995. - v.270. - p. 28495-28498.

407. Nicholson DW, Thornberry NA// Caspases: killer proteases. //Trends Biochem Sci. 1997. - v.22. - p. 299-306.

408. Nicholson К. M., Anderson N. G. //The protein kinase B/Akt signaling pathway in human malignancy. // Cell Signal. 2002. v. 14. - p. 381-395.

409. Nishigaki I, Hagihara M, Tsunekawa H et al. / / Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. // Biochem Med. — 1981. — v. 25.-p. 373-378.

410. Nishikawa T, Edelstein D, Brownlee M//The missing link: a single unifying mechanism for diabetic complications.// Kidney Int. 2000. v.58. -p. 26-30.

411. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, et al // Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. //Nature. 1999. - v. 404. — p.787 —790.

412. Njoroge FG, Monnier VM //The chemistry of the maillard reaction underphysiological conditions: a review. // Prog Clin Biol Res. 1989. - v. 304.-p. 85-107.

413. Nourooz-Zadeh J., Tajaddini-Sarmadi J., Wolff S.R. // Relationship between plasma measures of oxidative stress and metabolic control in NIDDM. // Analyt.Biochem. 1994. - v. 220. - p. 403-409.

414. Nyomba B.L., Ossowski V. M., Bogardus C., Mott D. M. // Insulin sensitive tyrosine kinase: relationship with in vivo insulin action in humans. // Am. J. Physiol. 1990. - v. 258. - E964 - E974.

415. Oberley L.M. //Free Radic and Diadetes. // Free Radic. Biol. Med. 1988. -v. 5.-p. 113-124.

416. O'Brien R.C., Luo M.// The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro.// Methabolism.- 1997. — v. 46 (Suppl 1).-p.22-25.

417. O'Brien R.S., Luo MM Diabetes. 1996. - v. 45 (suppl. 1). - p. 36-39.

418. O'Brien R.C., Luo M., Balazs N., Mercuri J.// In vitro and in vivo antioxidant properties of gliclazide.//J. Diabetes Complications. 2000. — v. 14.-p. 201-206.

419. Offermanns S; Schultz G. // Complex information processing by the transmembrane signaling system involving G proteins. // Naunyn Schmiedebergs Arch. Pharmacol. 1994. - v.350. - p. 329-338.

420. Ohrvall M., Nalsen С. and Vessby В. // Vitamin E Improves the Antioxidative Capacity but Not the Insulin Sensitivity in Elderly Men. //Nutr. Metab. Cardiovasc. Dis. 1997. - v. 7. - p. 9-15.

421. Okado A., Kawasaki Y., Hasuike Y., Takahashi M., Teshiva Т., Fujii J., Taniguchi N. // Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. //Biochem. Biophys. Res. Commun. 1996. -v.225.-p. 219-224.

422. Olczyk K, Koscielniak Kocurek E, Sonecki P, Zdenkowski W//The lipid peroxidation products and the enzymes of antioxidant system in patients with diabetes mellitus. //Rocz. Akad. Med. Bialymst. 1994. - v.39. - p. 93-9.

423. Oldreive C, Zhao K, Paganga G, Halliwell B, Rice-Evans С.// Inhibition of nitrous acid-dependent tyrosine nitration and DNA base deamination by flavonoids and other phenolic compounds.// Chem Res Toxicol. 1998. -v.ll.-p. 1574-1579.

424. Orchard TJ. // Dyslipoproteinemia and diabetes. // Endocrinol. Metab. Clin. North Am. 1990. - v.19. - p. 361-380.

425. Orekhov A. N., Grunwald J. // Effect of garlic on atherosclerosis// Nutrition. 1997. - v.13. - p. 656-663.

426. Orekhov A. N., Tertov V. V. /Яп vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells. / //Lipids. -1997.-v.32.-p. 1055-1060.

427. Orlowski J.// Heterologous expression and functional propeties of amilorid high affinity NHE-1 and low affinity NHE-3 isoforms of the rat Na+/tf exchanger. // J. Biol. Chem. 1993. - v. 268. - p. 16369-16377.

428. Orlowski J., Kandasamy R.A., Shull G.E. // Molecular cloning of putative members of Na+/H+ exchanger gene family. // J. Biol. Chem. 1992. — v. 267.-p. 9331-9339.

429. Ou С С, Tsao SM, Lin MC, Yin MC// Protective action on human LDL against oxidation and glication by four organosulfur compounds derived from garlic.//Lipids. 2003. - v. 38. - p. 219-224.

430. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J //Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability.//J Biol Chem. 2000. - v.275. - p. 26484-91.

431. Paglia D. E.,Valentine W. N.//J Lab Clin Med.-1967. v.70. - p.158-167.

432. Paolisso G, D'Amore A, Giugliano D, Ceriello A., Varricchio M./// Pharmacological Doses of Vitamin E Improve Insulin Action in Healthy Subjects and Non-Insulin-Dependent Diabetic Patients. // Am J Clin Nutr. -1993. v.57. - p.650-656.

433. Paolisso G, D'Amore A,Galzerano D, Balbi V,Giugliano D„ Varricchio M, D'Onofrio F.// Daily Vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. // Diabetes Care. 1993. - v.16.-p.1433-1437.

434. Paolisso G, Di Maro G, Pizza G, D'Amore A, Sgambato S, Tesauro P, Varricchio M, D'Onofrio F //Plasma GSH/GSSG affects glucose homeostasis in healthy subjects and non-insulin-dependent diabetics. // Am J Physiol. -1992. v. 263. - E435-E440.

435. Paolisso G, Giugliano D. // Oxidative stress and insulin action: is there a relationship? // Diabetologia. 1996. - v. 39. - p. 357-363.

436. Park J-Y, Takahara N, Gabriele A et al. //Induction of endothelin-1 expression by glucose: an effect of protein kinase С activation. // Diabetes. 2000. - v. 49. - p. 1239-1248.

437. Parker GJ, Lund КС, Taylor RP, McClain DA// Insulin resistance of glycogen synthase mediated by o-linked N-acetylglucosamine.// J Biol Chem. 2003. - v. 278. - p. 10022-10027.

438. Parthasarathy S., Young S.G., Witztum J.L., Pittman R.C. // Probucol inhibits oxidative modification of low density lipoprotein. // J. Clin. Invest. 1986. - v.77. - p. 641-644.

439. Parthiban A.; Yijayalingam S.; Shanmugasundaram K.R.; Mohan R.// Oxidative stress and the development of diabetic complications antioxidants and lipid peroxidation in erythrocytes and cell membrane. // Cell Biol. Int. — 1995.-v. 19.-p. 987-993.

440. Pasantes-Morales H, Cruz C. //Taurine and hypotaurine inhibit light-induced lipid peroxidation and protect rod outer segment structure. // Brain Res. 1985. - v. 330. - p. 154-157.

441. Pavlovic D, Andersen NA, Mandrup-Poulsen T, Eizirik DL //Activation of extracellular signal-regulated kinase (ERK) 1/2 contributes to cytokine-induced apoptosis in purified rat pancreatic 3-cells. // Eur Cytokine Netw. -2000.-v.ll.-p. 267-274.

442. Pawson Т., Scott J. D. //Signaling through scaffold, anchoring, and adaptor proteins. // Science. 1997. - v.278. - p. 2075-2080.

443. Persson S.U.; Wohlfart G.; Larsson H.; Gustafson A. //Correlations between fatty acid composition of the erythrocyte membrane and blood rheology data. // Scand. J. Clin. Lab. Invest. 1996. - v. 56. - p. 183-190.

444. Pestell KE, Ducruet AP, Wipf P. //Small molecule inhibitors of dual specificity protein phosphatases.//Oncogene. 2000. — v. 19. - p. 6607-6612.

445. Pfeiffer A., Schatz H. //Diabetic microvascular complications and growth factors. // Exp. Clin. Endocrinol. Diabetes. 1995. - v. 103. - p. 7-14.

446. Phillips S, Thornalley P. //The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methilglyoxal. // Eur. J. Biochem. 1993. - v.212. - p. 104-105.

447. Pirart J. // Diabetes mellitus and its degenerative complications: A prospective study of 4400 patients observed between 1947 and 1973. //Diabetes Care. 1978.-v. l.-p. 168-188.

448. Pjodkowaki RA, Grotz VL, Mudalar S, Henry RBJ/ The effects of alphalipoic acid on glucose homeostasis in type 2 diabetes. //J Invest Med . — v. 50. 71A.

449. Poitout V, Olson LK, Robertson RP //Chronic exposure of betaTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3bl insulin gene transcription activator.// J Clin Invest. 1996. - v. 97. -p. 1041-1046.

450. Poitout V, Robertson RP// Minireview: secondary 3-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. //Endocrinology. 2002. v.143. - p. 339-342.

451. Porte Jr D// Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. // Diabetes Metab Res Rev. 2001. - v. 17. - p. 181-188.

452. Pouyssegur J. et al. //Mechanisms of activation and molecular genetics of the mammalian №+/КГ antiporter. // In: pH homeostasis. - Haussinger D. ed. - London, Academic press .— 1988. - P. 61.

453. Prevention CffiCa. //Trends in the prevalence and incidence of self reported diabetes mellitus: United States, 1980-1994. //Morbidity and Mortality Weekly Report. 1997.-v. 46.-p. 1014-1018.

454. Qiao LY, Goldberg JL, Russell JC, Sun XJ//Identification of enhanced serine kinase activity in insulin resistance.//.! Biol Chem. 1999. — v. 274. -p.10625—10632.

455. Quyyumi AA // Endothelial function in health and disease: new insights into the genesis of cardiovascular disease.//Am J Med. 1998. - v. 105. -32S-39S.

456. Rabini RA., Staffolani R., Fumelli P., Mutus В., Curatola G., Mazzanti L. // Decreased nitric oxide syntase activity in platelets EDDM and NIDDM patients. // Diabetologia. 1998. - v.41. - p. 101-104.

457. Rahier J, Goebbels RM & Henquin JC. //Cellular composition of the human diabetic pancreas. // Diabetologia. 1983. — v. 24. — p. 366-371.

458. Randle P.J., Garland P.B., Hales C.N. et al. // The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. //Lancet. 1963. - v. 1.-p. 785-789.

459. Rao MS, Reddy JK // Peroxisomal B-oxidation and steatohepatitis. // Semin Liver Dis. 2001. - v. 21 - p. 43-55.

460. Ravussin E, Smit SR. // Increased fat uptake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus.//Ann N Y Acad Sci. 2002. - v. 967. - p. 363378.

461. Reaven GM //Role of insulin resistance in human disease.// Diabetes. -1988.-v. 37.-p. 1595-1607.

462. Reaven GM, Brand RJ, Chen ID, Mathur AK, Goldfine ID// Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. // Diabetes. 1993. - v.42. - p. 1324-1332.

463. Reaven GM, Hollenbeck CB, Chen ID.// Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. //Diabetologia 1989 - v.32. - p. 52-5.

464. Reaven P.D., Herold D.A., Barnett J. and Edelman S. // Effects of Vitamin E on Susceptibility of Low-Density Lipoprotein and Low-Density Lipoprotein Subfractions to Oxidation and on Protein Glycation in NIDDM. //Diabetes Care. 1995.-v. 18.-p. 807-816.

465. Reccia R., Pignalasa B.,Grasso A., Campanella G. //Taurine treatment in retinits pigmentosa.//Acta Neurologica. 1980. — v.18.-p.132-136.

466. Regan TJ, Jyothirmayi GN, Laham C, Jain A. // Left ventricular diastolic dysfunction in diabetic or hypertensive subjects: role of collagen alterations. // Adv Exp Med Biol. 2001. - v. 498. - p. 127-32.

467. Reithmeier R.A. // Mammalian exchangers and co-transporters. // Curr. Opin. Cell Biol. 1994. - v. 6. - p. 583-594.

468. Rema M.; Mohan V.; Bhaskar A.; Shanmugasundaram K.R. //Does oxidant stress play a role in diabetic retinopathy? //Indian J. Ophthalmol. — 1995.-v. 43.-p. 17-21.

469. Reusch J. // Diabetes, microvascular complications and cardiovascular complications: what about glucose? //J Clin Invest. 2003. - v. 112. -p. 986-988.

470. Richard DE, Berra E, Pouyssegur J // Angiogenesis: how a tumor adapts to hypoxia. // Biochem Biophys Res Commun. 1999. - v.266. - p.718-722.

471. Richard J. P. // Mechanism for the formation of methylglyoxal from triosephosphates. // Biochem. Soc. Trans. 1993. - v. 21. - p. 549-553.

472. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, Allenberg J, Otto G, Roth H, Bierhaus A Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. // Am J Pathol. 1995. -v. 146.-p. 688-694.

473. Ritz E., Nowicki M., Fliser D., Homer D., Klimm H.P. //Proteinuria and hypertension. // Kidney Int. 1994. - v.46 (Suppl.). -S76-S80.

474. Robak J., Gryglewsky R J. //Flavonoids are scavenders of superoxide anions. // Biochem Pharmacol. 1988. - v. 37. - p. 837-842.

475. Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF //Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.// J Clin Invest. -1992. v. 90.-p. 320-325.

476. Robinson R, Robinson LJ, James DE, Lawrence Jr JC //Glucose transport in L6 myoblasts overexpressing GLUT1 and GLUT4.// J Biol Chem. 1993. -v. 268-p. 22119-22126.

477. Rosen P., Zink S., Tscope D. // Vascular damage due to oxidative stress: A pathogenetic concept for diabetic macro- and microangiopathy? Structual and Functional Abnormalities in Subclinical Diabetic Angiopathy. //BasehKarger. 1992. - p. 23-31.

478. Ross R. //Atherosclerosis an inflammatory disease see comments. // N Engl J Med. - 1999. - v.340. p. 115-126.

479. Ross WM., Creighton MO., Stewart-De Haan PJ., Sanwal M., Hirst M., Trevithick JR//Modelling conical cataractogenesis. In vivo effects of vitamin E on cataractogenesis in diabetic rats.//Can J Ophthalmol. — 1982. v. 17. — p. 61-6.

480. Rosskopf D., Hartung K., Hense J., Siffert W. // Enhanced immunoglobulin formation of immortalized В cells from hypertensive patients. // Hypertension. 1995. - v. 26. - p. 432-435.

481. Rosskopf D., Schroder. K-J., Siffert W. // Role of sodium-hydrogen exchange in the proliferation of immortalised lymphoblasts from patients with essential hypertension and normotensive subjects. // Cardiovasc. Res. -1995.-v.29.-p. 254-259.

482. Ruderman N.B., Haudtnschild C. // Diabetes as an atherogenic factor. // Prog. Cardiovasc. Dis. 1984. - v. 26. - p. 373-412.

483. Rudich A, Kozlovsky N, Potashnik R, Bashan N //Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes.// Am J Physiol. 1997. - v. 35. - E935-E940.

484. Ruggiero D, Lecomte M, Rellier N, Lagarde M, Wiernsperger N. // Reaction of metformin with reducing sugars and dicarbonyl compounds (Abstract). //Diabetologia, 1997. - v. 40 (suppl. 1). - A310.

485. Ruggiero-Lopez D, Lecomte M, Rellier N, Lagarde M, Wiernsperger N. // Reaction of metformin with reducing sugars and dicarbonyl compounds (Abstract). Diabetologia. 1997. - v. 40 (suppl. 1). - A310

486. Ruggiero-Lopez D, Howell SK, Szwergold BS, Wiernsperger N, Beisswenger PJ. // Metformin reduces methylglyoxal levels by formation of a stable condensation product (Triazepinone) Abstract). // Diabetes. 2000. -v. 49 (suppl. I). - A124.

487. Ruiz Palomo F.; Toledo T. // Primary Na+/H+ exchanger dysfunction: a possible explanation for insulin resistance syndrome. // Med. Hypotheses. -1993.-v.41.-p. 186-189.

488. Sage S. 0., Merritt J. E., Hallam T. J., Rink T. J. // Receptor-mediated calcium entry in fura-2-loaded human platelets with ADP and thrombin. // Biochem J. 1989. - v. 258. - p. 923-926.

489. Saito K. Yaginuma N & Takahashi T. // Differential volumetry of А, В and D cells in the pancreatic islets of diabetic and nondiabetic subjects. // Tohoku Journal of Experimental Medicine. 1979. — v.129. — p.273-283.

490. Sakahira H, Enari M, Nagata S// Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis.// Nature. 1998. — v. 391.-p. 96-99.

491. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu С &Yagihashi S. // Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. // Diabetologia. 2002. - v. 45. - p. 85-96.

492. Saltiel A. R., Kahn C. R. //Insulin signaling and the regulation of glucose and lipid metabolism. //Nature. 2001. - v. 414. - p. 799-806.

493. Salvemini D., De Nucci G., Vane JR. // Superoxide dismutase cooperales with prostacyclin to inhibit platelet aggregation: a comparative study in washed platelets and platelet rich plasma.//Thromb Haemost. 1991. - v. 65. -p. 421-424.

494. Sang K-H. L. Q., Lantoine F., Devynck M A. // Influence of authentic nitric oxide on basal cytosolic (Ca++)i and Ca++ release from internal stores in human platelets.//Br J Pharmacol. 1996. - v. 119. — p. 13611366.

495. Sardas S., Yilmaz M., Oztok LI, Cakir N. and Karakaya A.E. //Assessmentof DNA Strand Breakage by Comet Assay in Diabetic Patients and the Role of Antioxidant Supplementation.// Mutation Res. 2001. - v.490. - p. 123-9.

496. Sasaki H, Ray PS, Zhu L, Galang N, Maulik N //Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: possible role of NF«B.//Toxicology 2000. - v. 155. - p.27-35.

497. Schaeffer G., Wascher T. S., Kostner G. M, Graer W. F. //Alterations2+in platelet С a signalling in diabetic patients is due to increased formation of superoxide anions andreduced nitric oxide production. // Diabetologia. 1999. - v.42. - p. 167-176.

498. Shain W, Martin D.L. // Uptake and release of taurine — an overview. // Prog Clin Biol Res. 1990. - v. 351. - p. 243-252.

499. Sheela C. G., Augusti К. T. //Antidiabetic effects of S-allyi cysteine suphoxide isolated from garlic Allium sativum Linn. // Indian J. Exp. Biol. -1992.-v. 30.-p. 523-526.

500. Sheela C. G., Kumud K., Augusti К. T. // Anti-diabetic effects of onion and garlic sulfoxide amino acids in rats. //Planta Med. 1995. - v. 61. - p. 356-357.

501. Schmidt A.M., Hori O, Cao R, Yan S.D, Brett J.,Wautier J-L, Ogawa S, Kuwabara K, Matsumoto M, Stern D. // RAGE: a novel cellular receptor for advanced glycation end-products. // Diabetes 1996. — v. 45(Suppl.3). - S77-S80.

502. Schidt A.M., Mora R., Cao R. et al. //The endothelial cell binding site for advanced glycation end products consisst of a complex: an integral membrane protein and a lactoferrin-like polypeptide // J. Biol. Chem . 1994. -v. 269.-p. 9882-9888.

503. Schmidt AM, Stern DM //RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. //Trends Endocrinol Metab. 2000. - v. 11. - p. 368-375.

504. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D // Regulationof human mononuclear phagocyte migration by cellsurface-binding proteins for advanced glycation end products. // J Clin Invest.- 1993. -v. 91.-p. 2155-2168.

505. Schmidt AM, Yan SD, Wautier JL, Stern D. //Activation of receptor for advanced glycation end products: a mechanism forchronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. // Circ Res. 1999. - v. 84. - p. 489-497.

506. Schroeder F.; Woodford J.K.; Kavecansky J.; Wood W.G.; Joiner C. // Cholesterol domains in biological membranes. //Mol. Membr. Biol. 1995. — v. 12. - p. 113-119.

507. Shahidi F., Wanasundara P. //Phenolic Antioxidants./ Crit. Rev. //Food Sci. Nutr. 1992. - v. 32. - p. 67-103.

508. Sharma K., Ziyadeh F.N. //Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. // Sem.Nephrol. 1997.-v. 17.-p. 80-92.

509. Sharma, A., Kharb, S., Chugh, S.N., Kakkar, R. and Singh, G.P.// Evaluation of Oxidative Stress Before and After Control of Glycemia and After Vitamin E Supplementation in Diabetic Patients. // Metabolism. 2000. -v. 49.-p. 160-162.

510. Sheela C. G., Augusti К. T. //Antidiabetic effects of S-allyi cysteine suphoxide isolated from garlic Allium sativum Linn. // Indian J. Exp. Biol. -1992.-v. 30.-p. 523-526.

511. Sheela C. G., Kumud K., Augusti К. T. // Anti-diabetic effects of onion and garlic sulfoxide amino acids in rats. //Planta Med. 1995. — v. 61. - p. 356-357.

512. Sheela C. G., Kumud K., Augusti К. T. // Anti-diabetic effects of onion and garlic short term feeding to normal rats. // Experientia. 1975. - v. 31. -p. 148-149.

513. Shigenaga MK, Hagen TM, Ames BN.//Oxidative damage and mitochondrial decay in aging.// Proc Natl Acad Sci USA. 1994. - v. 91. - p. 10771-8.

514. Shimabukuro M, Higa M, Zhou Y-T, Wang M-Y, et al. // Lipoapoptosis inbeta-cells of obese prediabetic fa/fa rats: role of serine palmitoyl transferase overexpression.// J Biol Chem. 1998. - p. 273. -p. 32487-32490.

515. Shimabukuro M, Ohneda M, Lee Y, Unger RH// Role of nitric oxide in obesity-induced p-cell disease.// J Clin Invest 1997. - v. 100. - p. 290-295.

516. Shimabukuro M, Zhou Y-T, Levi M, Unger RH //Fatty acid-induced (3 cell apoptosis: a link between obesity and diabetes. // Proc Natl Acad Sci USA.1998. v. 95. - p. 2498-2502.

517. Siczkowski M., Davies J.E., Sweeney F.P., Kofoed Enevoldsen A., Ng L. //Na+/H+ exchanger isoform-1 abundance in skin fibroblasts of type I diabetic patients with nephropathy. //Metabolism. 1995. - v. 44. - p. 791-5.

518. Siess W. // Molecular mechanisms of platelets activation.// Physiol Rev. 1989. - v. 69. - p. 48-178.

519. Siffert W, Rosskopf D., Moritz A., Wieland Т., Kaldenberg-Stasch S.// Enhanced G-protein activation in immortalized lymphoblasts from patients with essential hypertension. // J. Clin. Invest. 1995. - v. 96. - p. 759-766.

520. Siffert W.; Dusing R. // Sodium-proton exchange and primary hypertension. An update. // Hypertension. 1995. - v. 26. — p. 649-655.

521. Siffert W.; Dusing R. //Na+/H+ exchange in hypertension and in diabetes mellitus — facts and hypotheses. // Basic Res Cardiol. 1996. — v. 91. - p. 179-190.

522. Singh R, Barden A, Mori T, Beilin L //Advanced glycation end-products: a review. // Diabetologia. 2001. — v.44. — p. 129-146.

523. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS //Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease.// J Hum Hypertens.1999.-v.13.-p. 203-208.

524. Siperstein MD. // Capillary basement membranes and diabeticmicroangiopathy.// Adv Intern Med. 1972. - v. 18. - p. 325-344.

525. Sitprija S., Plengvidhya C., Kangkaya V., Bhuvapanich S., Tunkayoon M. // Garlic and diabetes mellitus. Phase П clinical trial// J. Med. Assoc. Thai. -1987. Vol. 70(Suppl.2) - 223-227.

526. Sjoholm A, Honkanen RE, Berggren PO // Inhibition of serine/threonine protein phosphatases by secretagogues in insulin-secreting cells. // Endocrinology. 1995. - 136. - p. 3391-3397.

527. Skibola CF, Smith MT. //Potential health impacts of excessive flavonoid intake.// Free Radic Biol Med. 2000. - v.29. - p. 375-83.

528. Skyler JS. // Relationship of metabolic control of diabetes mellitus to chronic complications.//In Rifkin H, Porte D (eds): Diabetes Mellitus: Theory & Practice, ed 4. New York, Elsevier Science Publishing. - 1990. — pp 856-868.

529. Sobenin I. A., Maksumova M. A., Slavina E. S., Balabolkin M. I., Orekhov A. N.//Sulfonylureas induce cholesterol accumulation in human intimal cells and macrophages//Atherosclerosis. 1994. - v. 105. - p. 159-163.

530. Song YS, Rosenfeld ME. //Methionin-induced hyperhomo-cysteinemia promote superoxide anion generation and NF kappaB activation in peritoneal macrophages of C57BL/6mice. // J Med Food. 2004. - v.7(2). - p. 229-234.

531. Sotaniemi EA, Haapakoski E, Rautio A. //Ginserg therapy in non-insulin-dependent diabetic patients. // Diabetes Care. 1995. — v.l8. - p. 1373-1375.

532. Srivastava S., Joshi CS., Sethi PP., Agrawal AK., Srivastava SK., Seth PK. // Altered platelet functions in non-insulin-dependent diabetes mellitus (NIDDM). //Thromb. Res. 1994. -v.76.-p. 451-61.

533. Standaert M.L., Galloway L., Karnam P., Bandyopadhyay G., Moscat J., Farese R. V. // Protein kinase C-zeta as a downstream effector of phosphatidyl inositol 3-kinase during insulin stimulation on rat adipocytes.

534. Potential role on glucose transport. // J. Biol. Chem. 1997. - v. 272. — p. 30075-30082.

535. Standi E, Schnell O. //A new look at the heart in diabetes mellitus: from ailing to failing. // Diabetologia. 2000. - v. 43. - p. 1455-69.

536. Stasek JE, Patterson C, Garcia JGN //Protein kinase С phosphorylates caldesmon-77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial monolayers. // J Cell Physiol.- 1992.-v. 153.-p. 62-75.

537. Stefan N, Stumvoll M. //Adiponectin-its role in metabolism and beyond. // Horm Metab Res. 2002. - v. 34. - p. 469-474.

538. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y & UngerRH.// Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans.// Diabetes. 1982. - v. 31. - p. 694-700.

539. Steinberg D., Lewis A. //Oxidative modification of LDL and atherogenesis // Circulation. 1997. - v. 95. - p. 1062-1071.

540. Steinbrecher UP, Witztum JL// Glucosylation of low-density lipoproteinsto an extent comparable to that seen in diabetess lows their catabolism. //Diabetes. 1984. - v. 33. - p.130-134.

541. Stern M.P.; Haffiier S.M. // Dyslipidemia in type II diabetes. Implications for therapeutic intervention. // Diabetes Care. 1991. - v.14. - p. 1144-1159.

542. Stork P. J., Schmitt J. M. //Crosstalk between cAMP and MAP kinase signaling in regulation of cell proliferation.//Trends Cell Biol. 2002. — v. 12.- p. 258-266.

543. Strain J.//Disturbances of micronutrient and antioxidant status in diabetes.// Proc Nutr Soc. -1991. v.50. - p. 591-604.

544. Studer RK, Craven PA, DeRubertis F. // Role for protein kinase С in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. // Diabetes.-1993.- v. 42.-p. 118-126.

545. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ //Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. // Nature. 1991. - v.352. — p. 73-77.

546. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, Lane WS, Pierce JH, White MF //Role of IRS-2 in insulin and cytokine signaling. //Nature. 1995. - v. 377.-p.173-177.

547. Sundaram R.K.; Bhaskar A.; Vijayalingam S.; Viswanathan M.; Mohan R.; Shanmugasundaram K.R. //Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. // Clin. Sci.- 1996. -v. 90.-p. 255-260.

548. Suzuki H, Kurihara Y, Takeya M, Kamada N et al. //A role for macrophage scavender receptors in atherosclerosis and susceptibility to infection.//Nature. 1997. - v. 386. - p. 292-296.

549. Sykiotis GP, Papavassiliou AG //Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance.// Mol Endocrinol. 2001. - v. 15. - p. 1864-1869.

550. Szenasi P., Toth L., Ramies L. et al. //Platelet hyper- and hypoaggregability different microangiopathic complication of diabetes mellitus. // Acta diabetol. Lat. 1988. - v.25. - p. 7-12.

551. Szczeklik A., Gryglewski R.J., Domagala B. et al. // Serum lipoproteins, lipid peroxides and prostacyclin biosyntesis in patients with coronary heart disease// Prostaglandins. 1981. - v.22. - p. 795-807.

552. Szwergold B.S., Kappler F., Brown T.R. // Identification of fructoses-phosphate in the lens of diabetic rats.//Science. 1990. — v. 247. — p. 451-454.

553. Tajiri Y, Moller C, Grill V //Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits (3-cell function. //Endocrinology. 1997. -v.138.-p. 273-280.

554. Takagi C, Bursell SE, Lin Y-W et al. // Regulation of retinal haemodynamics in diabetic rats by increased expression and action of endothelin-1. // Invest Ophthalmol Vis Sci. 1996. - v. 37. - p. 25042518.

555. Takeishi Y, Chu G, Kirkpatrick DM et al /Лn vivo phosphorylation of cardiac troponin-I by protein kinase C-piI decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts. // J Clin Invest. -1998.-v. 102.-p. 72-78.

556. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP //Prevention of glucose toxicity in ШТ-Т15 cells and Zucker diabetic fatty rats by antioxidants. // Proc Natl Acad Sci U S. 1999. A96. - p. 10857 -10862.

557. Tanaka Y, Iwamoto H, Onuma T, R. K. //Inhibitory effect of metformin on formation of advanced glycation end products. //Curr Ther Res. 1997. — v. 58.-p. 693-697.

558. Tanaka Y, Tran PO, Harmon J, Robertson RP //A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity.// Proc Natl Acad Sci USA.- 2002. v. 99. -p. 12363-12368.

559. Tanaka Y, Uchino H, Shimizu T, et al. // Effect of metformin on advanced glycation endproduct formation and peripheral nerve function instreptozotocin-induced diabetic rats. // Eur J Pharmacol. — v. 376. — p. 17-22.

560. Tanaka S., Yashiro A., Nakashima Y., Nanri H., Ikeda M. //Plasma nitrite/nitrate level is inversly correlated with plasma low density lipoprotein cholesterol level.//Clin.Cardiology. 1997. - v. 20. - p. 361-365.

561. Taskinen M.R. // Hyperlipidaemia in diabetes. // Baillieres Clin. Endocrinol. Metab. 1990. - v. 4 - p. 743-775.

562. Tate RM., Morris HG., Schroeder WR., Repine JE.// Oxygen metabolites stimulate thromboxane production and vasoconstriction in isolated salineperfused rabbit lung.// J. Clin. Invest. 1984. - v. 74. - p. 608-613.

563. Tertov V.V., Kaplun V.V. Dvoryantsev S.N. et al. // Apolipoprotein B-bound lipids as a marker for evaluation of low density lipoproten oxidation in vivo // Biochem. Biophys. Res. Commun. 1995. — v.214. - p. 608-613.

564. Tesfamariam B. // Free radicals in diabetic endothelial cell disfunction. //Free Rad Biol Med. 1994. - v. 16. - p. 383-391.

565. Theriault A., Wang Q., Van Iderstine SC., Chen В., Franke AA., Adeli К.// Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid. // J. Lipid. Res. 2000. - v. 41. - p. 1969-1979.

566. Thompson A.L., Lim-Fraser M., KraegenE.W. //Effect of individual fatty acids on glucose uptake and glycogen synthesis in soleus muscle in vitro. //Lung Cellular and Molecular Phys. 2000. - v. 279(Is.3). - E577- E584.

567. Thornalley P.//Modification of the glyoxalase system in disease processes and prospects for therapeutic strategies./ZBiochem. Soc Trans. 1993. -v. 21. -p. 531-534.

568. Thornalley P.J.// Pharmacology of methylglyoxal: formation, modification of proteins and nucleis acids, and enzymatic detoxification — a role in pathogenesis and antiproliferative chemotherapy. // Jen Pharmacol. 1996. — v. 27.-p. 565-573.

569. Ting HH, Timini FK, Bolis KS, Creager SJ, Gans P, Creager MA.// Vitamin С improves Endotelium-Dependent Vasodilatation in Patients with Non-Insulin-Dependent Diabetes Mellitus. // J Clin Invest. 1996. — p. 97. -p. 22-28.

570. Tobey T.A.; Greenfield M; Kraemer F; Reaven G.M. // Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. // Metabolism. 1981.-v. 30.-p. 165-171.

571. Toborek M, Hennig В Fatty acid-mediated effects on the glutathione redox cycle in cultured endothelial cells. // Am J Clin Nutr. 1994. - v. 59. -p. 60-65.

572. Toker A., Cantley L. C. //Signaling through the lipid products of phospho-inositide-3-OH-kinase. // Nature. 1997. - v. 387. - p. 673-676.

573. Tonks NK, Neel BG //Combinatorial control of the specificity of protein tyrosine phosphatases.// Curr Opin Cell Biol. 2001 - v. 13. - p. 182-195.

574. Touyz RM, Schiffrin E. //Growth factors mediate intracellular signalling in vascular smooth muscle cells through protein kinase C-linked pathways. //Hypertension. 1997. - v. 30. - p. 1440-1447.

575. Trachtman H, Futterweit S, Bienkowski RS //Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells.//Biochem Biophys Res Commun 1993. - v. 191- p.759- 65.

576. Trachtman H, Futterweit S, Maneska J, Baynes J, et al //Taurine ameliorates chronic streptozocin-induced diabetes nephropathy in rats. // Am J Physiol. 1995. - v.269 (Renal, Fluid Electrolyte Physiol 38) - F429-F438.

577. Tran K, Proulx PR, Chan AC//Vitamin E suppresses diacylglycerol (DAG) level in thrombin-stimulated endothelial cells through an increase of DAG kinase activity.//Biochim Biophys Acta. 1994. - v.1212. - p. 193202.

578. Trevisan R.; Viberti G. //Sodium-hydrogen antiporter: its possible role in the genesis of diabetic nephropathy.//Nephrol. Dial. Transplant. 1997-v.12. -p. 643-645.

579. Trovati M, Massucco P., Mattiello L. // The insulin-induced increase of guanosine-3, 5-cyclic monophosphate in human platelets is mediated by nitric oxide. // Diabetes. 1996. - v. 45. - p. 768-770.

580. Tsai EC, Hirsch IB, Brunzell JD, et al. // Reduced plasms peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlledIDDM. //Diabetes. 1994. - v. 43. - p. 1010-1014.

581. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME // Protein kinase С involvement in the regulation of angiogenesis.// J Vase Res. 1993.- v. 30. — p. 202-208.

582. Turner R, Cull C, Holman R //United Kingdom Prospective Diabetes Study 17: The effect of improved metabolic control on complications in NIDDM. // Ann Intern Med. 1996. - v. 124. - p. 136-145.

583. Turrens JF, Boveris A //Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. // Biochem J. 1980. — v. 191. -p. 421-427.

584. UK Prospective Diabetes Study Group // Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). //Lancet. 1998. - v. 352. - p. 837-853.

585. UK Prospective Diabetes Study (UKPDS) Group. //Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). // Lancet. 1998. - v. 352. - p. 854-65.

586. UKPDS Group. //Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observation study. // BMJ. 2000. - v. 321. - p. 405-413.

587. UKPDS 38. //Tight blood pressure control and risk of macrovaskular and microvaskular complications in type 2 diabetes. // BMJ. 1998. - v. 317. - p. 703-713.

588. Ulrich A., Bell J.R., Chen E. Y., Herrera R., Petruzelli L.M., Dull T.J.,Gray A.,Coussens L., Liao YC., Tsubokawa M. //Human insulin receptor and its relationship to the tyrosine kinasee family of oncogenes. // Nature . -1985.- v.313.-p. 756-761.

589. Unger RH, Zhou YT// Lipotoxicity of 13-cells in obesity and in other causes of fatty acid spillover. // Diabetes. 2001. - v. 50(Suppl 1)- SI 18— S121.

590. Unger RH, Zhou YT, Orci L //Lipotoxicity. // In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. -Philadelphia: Lippincott Williams & Wilkins. - 2000. - p. 132-141.

591. United Kingdom Prospective Diabetes Study Group UK // Prospective Diabetes Study 16: Overview of 6 years' therapy of type П diabetes. A progressive disease. // Diabetes. 1995. — v. 44. — p. 1249-1258.

592. Uusitupa M., Niskanen L.K., Siitonen O. //Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type II diabetic and non-diabetic subjects. // Diabetologia. -1993.-v. 36.-p. 1175.

593. Van Dam P.S., Van Asbeck B.S., Erkelens B.W., Marx J.J.M., Gispen W-H,Bravenboer B. // The role of oxidative stress in neuropathy and other diabetic complications. //Diabetes Metab. Rev. 1995. - v. 11. — p. 181-192.

594. Van Gelder N.M.//Neuronal discharge hypersynchronicity and intracranial water balance in relation to glutamic acid and taurine redistribution: migraine and epilepsy. //Prog Clin Biol Res. 1990. - v. 351. - p. 1-20.

595. Vander Jagt D.L., Robinson В., Taylor K.K., Hunsaker L.A//Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. // J. Biol. Chem. 1992. - v. 267. -p. 4364-4369.

596. Vedavanam R., Srijayanta S., O'Reilly J. et al. //Antioxidant action and potential antidiabetic propeties of an isoflavonoid-containing soyabean phytochemical extract. // Pythother. Res. 1999. - v. 13. - p. 601- 608.

597. VergHS B.L. //Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. // Diabetes Metab. 1999. - v. 25(Suppl.3). - p. 32-40.

598. Vgotzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. // Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. // J. Clin Endocrinol Metab. 1997.-v. 82.-p. 1313-1316.

599. Vidgen E. //American Ginseng (panax quinquefolius L.) reduced postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. // Arch Intern Med. 2000. - v. 160. - p. 513-515.

600. Vijayalingam S., Parthiban A.; Shanmugasundaram K.R.; Mohan V. // Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. //Diabet. Med. 1996. - v. 13. — p. 715-719.

601. Violi F. et al. // Nitric oxide and its role in lipid peroxidation. 1999. //Diabetes metabolism research and reviews. 1996. - v. 15. — p. 283-288.

602. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A.// Cachectin/TNF and IL-1 induced by glucose-modified proteins:role in normal tissue remodeling.// Science. 1988. - v. 240. - p. 1546-1548.

603. Vlassara H, Bucala R, Striker L. // Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. //Lab Invest. 1994. - v. 70. - p. 138-151.

604. Vlassara H. // Recent progress in advanced glyxation end products and diabetic complicatins.// Diabetes. 1997. - v. 46 (Suppl. 2). - S19-S25.

605. Vosseller K, Wells L, Lane MD, Hart GW // Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. // Proc Natl Acad Sci USA. 2002. - v. 99. - p. 5313-5318.

606. Wang Z., Orlowski J., Shull G.E. // Primary structure and functional expression of a novel gastrointestinal isoform of the rat Na+/H+ exchanger. // J. Biol. Chem. 1993. - v. 263. - p. 11925-11928.

607. Watts GF, Playford DA// Dislipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis.//Atherosclerosis. 1998. - v. 141. - p.17-30

608. Weiss SJ, Klein R, Slivka A, Wei M. // Chlorination of taurine by human neutrophils.// J Clin Invest. 1982. - v. 70. - p. 598-607.

609. Westermark P, Willander E // The influence of amiloid deposits on the islet volume in maturity-onset diabetes mellitus. // Diabetologia. 1978. -v.15.-p. 417-421.

610. White M. F // The IRS-signalling system: a network of docking proteins that mediate. // Mol. Cell Biochem. 1998. - v. 182. p. 3-11.

611. White M. F., Kahn C. R. // The insulin signaling system. // J. Biol. Chem. 1994.-v. 259. p. 1-4.

612. WHO Study Group //Diabetes Mellitus. //World Health Organ Techn. Ser. 1985.- v. 727.-p. 1-113.

613. Williams В. // Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. // J Hyperten. 1995. - v. 13. - p. 477-486.

614. Williams B, Schrier RW. // Characterization of glucose-induced in situ protein kinase С activity in cultured vascular smooth muscle cells. //Diabetes. 1992. - v. 41. - p. 1464-1472.

615. Williams В., Howard R.L. //Glucose-induced changes in Na+/H+ antiport activity and gene expression in cultured vascular smooth muscle cells. Role of protein kinase С. II J. Clin. Invest. 1994 - v. 93. - p. 2623-2631.

616. Williams SB, Cusco JA, Roddy M, Johnstone MT, Creager MA. // Impaired nitric oxide mediated vasodilatation in patients with non-insulin dependent diabetes mellitus. //J Am Coll cardiol. 1996. - v.27. - p.771-776.

617. Williamson J.R., Chang K., Frangos M., et al // Hyperglycemic pseudohypoxia and diabetic complications. // Diabetes. 1993. - v.42. - p. 801-813.

618. Wilson M.J., Richter-Lowney K., Daleke D.L. //Hyperglycemmia induces a loss of phospholipid asymmetry in human erythrocytes. // Biochem. 1993. -v. 32.-p. 11302-11310.

619. Winocour P.D. //Platelet abnormalities in diabetes mellitus. // Diabetes. -1992. v. 41 (Suppl. 2).-p. 26-31.

620. Winocour P.D. // Platelets, vascular disease, and diabetes mellitus. // Can. J. Physiol. Pharmacol. 1994. - v. 72. - p. 295-303.

621. Wittmann I, Nagy J. // Are insulin resistance and atherosclerosis the consequences of oxidative stress?//Diabetologia. 1996 . — v. 39. — p. 1002-3.

622. Witztum J.L. // Role of modified lipoproteins in diabetic macroangiopathy.// Diabetes. 1997. - v. 46 (Suppl. 2). - SI 12-S114.

623. Witztum J.L., Steinberg D. //Role of oxidized low density lipoprotein in atherogenesis// J.Clin. Invest. 1991. - v. 88. - p. 1785-1792.

624. Wojtczak L, Schonfeld P. //Effect of fatty acids on energy coupling processes in mitochondria. // Biochim Biophys Acta. 1993. — v. 1183. — p. 41-57.

625. Wolff SP, Dean RT. //Glucose autoxidation and protein modification: the potential role of "autoxidative glycosylation" in diabetes. // Biochem J. — 1987. v. 245. - p. 243 -250.

626. World Health Organisation:"The World Health Report 1998. Life in 21st Century — a Vision for ALL" //Geneva: World Health Organisation, 1998.

627. Woods JW; Falk RJ; Pittman AW; Klemmer PJ; Watson BS; Namboodiri K.// Increased red-cell sodium-lithium countertransport in normotensive sons of hypertensive parents.// N. Engl. J. Med. 1982. - v. 306. - p. 593-595.

628. Wrobel J, Li ZN, Dietrich A, Mccaleb M, Mihan B, Sredy J, Sullivan D. // Nove 15-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-dionesas anti-hyperglycemic agents. // J Med Chem. 1998. - v. 41. - p. 1084-1091.

629. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-HayesD. // Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. // Am J Physiol. 1999. - v. 277. - C1229-C1238.

630. Wyllie AH, Kerr JF, Currie AR. // Cell death: the significance of apoptosis. //Int Rev Cytol. 1980. - v. 68. - p. 251-306.

631. Xia P, Inoguchi T, Kern TS, Engerman RL, Oats PJ, King GL. // Characterisation of the mechanism for the chronic activation of diacylglycerol-protein kinase С in diabetes and hypergalactosaemia. // Diabetes. 1994. v. 43. - p. 1122-1129.

632. Yamamoto K., Fukuda N., Shiroi S. et al. // Effect of dietary antioxidants on the susceptibility to hepatic microsomal lipid peroxidation in the rat. // Ann. Nutr. Metab. 1995. -v. 39,- p. 99-106.

633. Yan SD, Stern D, Schmidt AM. // What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. // Eur J Clin Invest. 1997.-v. 27.-p. 179-181.

634. Yang G. //Alteration on fatty acid components of erythrocyte membrane and insulin resistance in diabetic patients. // Chinese Medical Journal. 1998. -v.78.-p. 269-271.

635. Yaworsky K, Somwar R, Klip A. // Interrelationship between oxidative stress and insulin resistance. // In Antioxidants in Diabetes Management. -Packer L, Ro. sen P, Tritschler HJ, King GL, Eds. New York, Marcel Dekker. - 2000. - p. 275-302.

636. Yla-Herttuala S. // Oxidant stress as a critical determinant of endothelial function// Drugs Today. 1994.- v. 30. - p. 507-514.

637. Yoshimoto T, Furukawa M, Yamamoto S, Horie T, Watanabe-Kohno S. // Flavonoids: potent inhibitors of arachidonate 5-lipoxygenase. //Biochem BiophysRes Commun. 1983.-v. 116.-p. 612-614.

638. Yoshino G.; Hirano Т.; Kazumi T. // Dyslipidemia in diabetes mellitus. // Diabetes Res. Clin. Pract. 1996. - v. 33. - p. 1-14.

639. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE // Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption oflKKB.// Science. 2001. - v. 293. - p. 1673-1677.

640. Zeigler D, Reljanovid M, Melmert H, Gries FA // Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. // Exp Clin Endocrin Diabet. 1999. - v. 107. - p. 421-430.

641. Zentay Z., Raguwanshi M., Reddi A., Lasker N., Dasmahapatra A. // Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM. //J. Diabetes Complications. 1995. - v. 9. - p. 74-80.

642. Zhihua Wei, Benjamin H. S. Lau.// Garlic inhibits free radical generation augments antioxidant enzyme activity in vascular endothelial cells. // Nutrition Res. 1998. - v. 18. - p. 61-70.

643. Zhou YP, Grill V // Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. // J Clin Endocrinol Metab. 1995. - v. 80:1584-1590.

644. Zhou YP, Grill VE //Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. // J Clin Invest. 1994. - v. 93. - p. 870-876.

645. Zhou Y-T, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L,Unger RH //Lipotoxic heart disease in obese rats: implications for human obesity.// Proc Nad Acad SciUSA. 2000. - v.'97. - p. 1784-1789.375 ^

646. Zick Y //Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. // Trends Cell Biol. 2001. - v. 11. - p. 437-441.

647. Ziegler D, Gries FA // Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. // Diabetes. 1997. — v. 36 (Suppl 2). - 62S-66S.

648. Zou H, Li Y, Liu X, Wang X // An APAF-1 cytochrome с multimeric complex is a functional apoptosome that activates procaspase-9. // J Biol Chem. 1999. - v.274. - p. 11549-11556.

649. Zwaal R., Schroit A. // Pathophysiologic implication of membrane phospholipid asymmetry in blood cells. // Blood. 1997. -v. 89. — n.4. - p. 1121-1132.